WO2009016202A2 - Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen - Google Patents
Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen Download PDFInfo
- Publication number
- WO2009016202A2 WO2009016202A2 PCT/EP2008/059999 EP2008059999W WO2009016202A2 WO 2009016202 A2 WO2009016202 A2 WO 2009016202A2 EP 2008059999 W EP2008059999 W EP 2008059999W WO 2009016202 A2 WO2009016202 A2 WO 2009016202A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- fatty acids
- desaturase
- nucleic acid
- fatty acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
Definitions
- the present invention relates to polynucleotides from Helobdella robusta, Laccaria bicolor, Lottia gigantea, Microcoleus chthonoplastes, Monosiga brevicollis, Mycosphaerella fijiensis, Mycospaerella graminicola, Naegleria gruberi, Nectria haematococca, Nematostella vectensis, Phycomyces blakesleeanus, Physcomitrella patens, Postia placenta, Selaginella moellendorffii, Microdochium nivale and Trichoderma resii, which encode desaturases and can be used for the recombinant production of polyunsaturated fatty acids.
- the invention relates to vectors, host cells and transgenic non-human organisms containing the polynucleotides of the invention, as well as the polypeptides encoded by the polynucleotides.
- the invention also relates to antibodies against the polypeptides of the invention.
- the invention also relates to preparation processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions and their use as medicaments, cosmetics, foods, feedstuffs, preferably fish feed or dietary supplements.
- Fatty acids and triacylglycerides have a variety of uses in the food, animal nutrition, cosmetics and pharmaceutical industries. Depending on whether they are free saturated and unsaturated fatty acids or triacylglycerides with an increased content of saturated or unsaturated fatty acids, they are suitable for a wide variety of applications.
- Polyunsaturated fatty acids such as linoleic and linolenic acids are essential for mammals because they can not be produced by them. Therefore, polyunsaturated ⁇ -3 fatty acids and ⁇ -6 fatty acids are an important component of animal and human food.
- polyunsaturated ⁇ -3 fatty acids which are preferred in fish oils, is particularly important for food.
- the unsaturated fatty acid DHA is said to have a positive effect on the development and maintenance of brain functions.
- polyunsaturated fatty acids are referred to as PUFA, PUFAs, LCPUFA or LCPUFAs (poly unsaturated fatty acids, PUFA, polyunsaturated fatty acids, long chain polyunsaturated fatty acids, LCPUFA, long-chain polyunsaturated fatty acids).
- the free fatty acids are advantageously prepared by saponification.
- Common natural sources of these fatty acids are fish such as herring, salmon, sardine, perch, eel, carp, trout, halibut, mackerel, zander or tuna, or algae.
- oils with saturated or unsaturated fatty acids are preferred.
- lipids with unsaturated fatty acids especially polyunsaturated fatty acids, are preferred in the human diet.
- the polyunsaturated ⁇ -3 fatty acids thereby a positive effect on the cholesterol level in the blood and thus the possibility of preventing heart disease is attributed.
- ⁇ -3 fatty acids By adding these ⁇ -3 fatty acids to the diet, the risk of heart disease, stroke or hypertension can be significantly reduced.
- inflammatory especially chronic inflammatory processes in the context of immunological diseases such as rheumatoid arthritis can be positively influenced by ⁇ -3 fatty acids.
- omega-6 fatty acids such as arachidonic acid tend to have a negative effect on these diseases in these rheumatic diseases due to our usual food composition.
- ⁇ -3 and ⁇ -6 fatty acids are precursors of tissue hormones, the so-called eicosanoids such as the prostaglandins, which are derived from dihomo- ⁇ -linolenic acid, arachidonic acid and eicosapentaenoic acid, and the thromboxane and leukotrienes, which differ from of arachidonic acid and eicosapentaenoic acid.
- Eicosanoids which are formed from ⁇ -6 fatty acids, usually promote inflammatory reactions, while eicosanoids (so-called PG3 series) of ⁇ -3 fatty acids have little or no pro-inflammatory effect.
- Desaturase claimed Further desaturases are described, for example, in EP-A-0 550 162, WO 94/18337, WO 97/30582, WO 97/21340, WO 95/18222, EP-A-0 794 250, Stukey et al., J. Biol. Chem. , 265, 1990: 20144-20149, Wada et al., Nature 347, 1990: 200-203 or Huang et al., Lipids 34, 1999: 649-659.
- the biochemical characterization of the various desaturases has hitherto been inadequate, since the enzymes are very difficult to isolate and characterize as membrane-bound proteins (McKeon et al., Methods in Enzymol.
- microorganisms for example microalgae such as Phaeodactylum tricornutum, Porphiridium species, Thraustochytrien species, Schizochytria species or Crypthecodinium species, ciliates such as Stylonychia or Colpidium, fungi such as Mortierella, Entomophthora or Mucor and / or Moose such as Physcomitrella, preferably Physcomitrella patens, Ceratodon and Marchantia (R.Vazhappilly & F. Chen (1998) Botanica Marina 41: 553-558; K. Totani & K.
- microalgae such as Phaeodactylum tricornutum, Porphiridium species, Thraustochytrien species, Schizochytria species or Crypthecodinium species, ciliates such as Stylonychia or Colpidium, fungi such as Mortierella, Entomophthora or Mucor and
- EPA eicosapentaenoic acid
- DHA docosa- hexaenoic acid
- the polyunsaturated fatty acids can be divided according to their desaturation pattern into two large classes, in ⁇ -6 or ⁇ -3 fatty acids, which have metabolically and functionally different activities.
- the starting material for the ⁇ -6 pathway is the fatty acid linoleic acid (18: 2 ⁇ 9 12 ), while the ⁇ -3 pathway is via linolenic acid (18: 3 ⁇ 9 12 15 ).
- Linolenic acid is formed by the activity of a ⁇ 15-desaturase (Tocher et al., 1998, Prog. Lipid Res., 37, 73-117, Domergue et al., 2002, Eur. J. Biochem., 269, 4105-4113).
- ⁇ -3 fatty acids shows the therapeutic effect as described above in the treatment of cardiovascular diseases (Shimikawa 2001, World Rev. Nutr., Diet, 88, 100-108), inflammations (Calder 2002, Proc. Soc., 61, 345-358) and arthritis (Cleland and James 2000, J. Rheumatol., 27, 2305-2307).
- LCPUFAs in higher plants (preferably in oilseeds such as oilseed rape, linseed, sunflower and soybean), as this will enable large quantities of high quality LCPUFAs to be obtained inexpensively for the food, animal and pharmaceutical industries.
- genes coding for enzymes of the biosynthesis of LCPUFAs are introduced and expressed in oilseeds. These are genes which encode, for example, ⁇ 6-desaturases, ⁇ 6-elongases, ⁇ 5-desaturases or ⁇ 4-desaturases. These genes can be advantageously isolated from microorganisms and lower plants that produce LCPUFAs and incorporate them into the membranes or triacylglycerides.
- ⁇ 6-desaturase genes from the moss Physcomitrella patens and ⁇ 6 elongase genes from P. patens and the nematode C. elegans have already been isolated (Zank, TK et al., Plant Journal 31: 255-268, 2002, Beaudoin et al., Biochem Soc Trans 28: 661-663, 2000).
- the first transgenic plants which contain and express genes encoding enzymes of the LCPUFA biosynthesis and produce LCPUFAs have been described, for example, in DE 102 19 203 (Process for the Production of Polyunsaturated Fatty Acids in Plants). However, these plants produce LCPUFAs in quantities that need to be further optimized for processing the oils contained in the plants.
- the object underlying the present invention is to provide such means and measures.
- the object is achieved by the embodiments which are described in the patent claims and in the following.
- the present invention thus relates to a polynucleotide comprising a nucleic acid sequence which is selected from the group consisting of:
- nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences of (a) or (b) and which encodes a polypeptide having a desaturase activity;
- (d) Nucleic acid sequence for a fragment of a nucleic acid from (a), (b) or (c), wherein the fragment encodes a polypeptide having a desaturase activity.
- the ⁇ 6 fatty acid class starts from the ⁇ 6 fatty acid linoleic acid (18: 2 ⁇ 9,12), whereas the ⁇ 3 fatty acid class starts from the ⁇ 3 fatty acid linolenic acid (18: 3 ⁇ 9,12,15); see Figure 1.
- These two fatty acids are the substrates for the synthesis of long-chain ⁇ 6 or ⁇ 3 PUFAs. The increase in the content of these fatty acids according to the introduced genes leads to an increase in the content of long-chain PUFAs.
- the present invention provides polynucleotide sequences that result in an increase in the substrates 18: 2 ⁇ 9,12 and 18: 3 ⁇ 9, 12, 15, respectively.
- Polynucleotide sequences encoding enzymes having ⁇ 12-desaturase activity, ⁇ 12- and ⁇ 15-desaturase activity, ⁇ 15-desaturase activity or ⁇ 3-desaturase activity have been identified.
- polynucleotide refers according to the invention polynucleotides comprising nucleic acid sequences encoding polypeptides with desaturase activity.
- the desaturase activities are preferably needed for the biosynthesis of lipids or fatty acids. Particularly preferred are the following desaturase activities: ⁇ -12-desaturase, ⁇ -15-desaturase, ⁇ -12 and ⁇ -15 desaturase or omega-3-desaturase activity.
- the desaturases are preferably involved in the synthesis of polyunsaturated fatty acids (PUFAs) and more preferably in the synthesis of long-chain PUFAs (LCPUFAs).
- the desaturases according to the invention particularly preferably have activities, substrate specificities and / or conversion rates which are comparable to those of the respective homologous desaturase enzymes from Pythium irregular, Ostreococcus tauri, Phytophtora sojae or Phytophtora infestans.
- the specific polynucleotides according to the invention ie the polynucleotides having a nucleic acid sequence according to SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25 , 26, 90, 91, 122, 123, 125, 126, 128, 129, 131, 132, 134, 135, 142, 143, 145, 146, 148, 149, 151, 152, 154, 155 or 157 have been made Nectria haematococca, Trichoderma resii, Monosiga brevicollis, Mycosphaerella fijiensis, Mycospaerella graminicola (Septoria tritici), Naegleria gruberi, Phycomyces blakesleeanus, Nematostella vectensis, Helobdella robusta, Lottia gigantea, Microcoleus chthonoplastes, Laccaria bicolor, Physcom
- nucleic acid sequences according to SEQ ID NOS: 1, 2, 4 and 5 are from Nectria haematococca
- nucleic acid sequences according to SEQ ID NOS: 7 and 8 are from Trichoderma resii
- nucleic acid sequences according to SEQ ID NOS: 10 and 11 are from Monosiga brevicollis
- the Nucleic acid sequences according to SEQ ID NOS: 13, 14, 16 and 17 from Mycospaerella graminicola (Septoria tritici)
- nucleic acid sequences according to SEQ ID NOS: 19 and 20 from Naegleria gruberi
- nucleic acid sequences according to SEQ ID NOS: 22 and 23 from Phycomyces blakesleeanus
- nucleic acid sequences according to SEQ ID NOS: 25 and 26 from Nematostella vectensis
- nucleic acid sequences according to SEQ ID NOS: 90 and 91 from Laccaria bicolor
- SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 90, 122, 125, 128, 131, 134, 142, 145, 148, 151 and 154 are genomic Sequences, whereas SEQ ID NOS: 2, 5, 8, 11, 14, 17, 20, 23, 26, 91, 123, 126, 129, 132, 135, 143, 146, 149, 152, 155 and 157 Represent sequences (cds).
- SEQ ID NOs: 3, 6, 9, 12, 15, 18, 21, 24, 27, 92, 124, 127, 130, 133, 136, 144, 147, 150, 153, 156 and 158 show the related amino acid sequences.
- polynucleotides of the invention are polynucleotides encoding a polypeptide having ⁇ -12 desaturase activity and comprise (i) a nucleic acid sequence as shown in SEQ ID NO: 1 or 2, (ii) a nucleic acid sequence encoding a polypeptide shown in SEQ ID NO: 3, (iii) a nucleic acid sequence which is at least 70% identical to one of the Nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii), wherein the fragment encodes a polypeptide having a ⁇ -12-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 4 or 5, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 6 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having a ⁇ 15-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -12 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 10 or 11, (ii) a nucleic acid sequence encoding a polypeptide as set forth in SEQ ID NO: 12, (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii ), which fragment encodes a polypeptide having ⁇ 12-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 13 or 14, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 15 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), wherein the fragment encodes a polypeptide having a ⁇ -15 desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -12 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 16 or 17, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 18 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having ⁇ 12-desaturase activity.
- omega-3 desaturase especially ⁇ -15-desaturase
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 90 or 91, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 92 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having a ⁇ 15-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 128 or 129, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 130 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), wherein the fragment encodes a polypeptide having a ⁇ -15 desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 131 or 132, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 133 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having a ⁇ 15-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 134 or 135, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 136 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having a ⁇ 15-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 145 or 146, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 147 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), wherein the fragment encodes a polypeptide having a ⁇ -15 desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ 15-desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 148 or 149, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 150 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having a ⁇ 15-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 151 or 152, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 153 (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences from (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid from (i), (ii) or (iii) wherein the fragment encodes a polypeptide having a ⁇ 15-desaturase activity.
- Polynucleotides encoding a polypeptide having ⁇ -15 desaturase activity comprising (i) a nucleic acid sequence as shown in SEQ ID NO: 157, (ii) a nucleic acid sequence encoding a polypeptide as shown in SEQ ID NO: 158, (iii) a nucleic acid sequence which is at least 70% identical to one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), wherein the fragment encodes a polypeptide having a ⁇ -15 desaturase activity.
- delta-12 desaturase or ⁇ 12-desaturase or d-12 desaturase or d12-des or d12Des
- delta-12 desaturase or ⁇ 12-desaturase or d-12 desaturase or d12- Des or d12Des activity
- the C atoms C12 and C13 are dehydrogenated by one hydrogen atom, forming a double bond between these two C atoms.
- delta-15-desaturase or ⁇ 15-desaturase or d-15 desaturase or d15-des or d15Des
- delta-15-desaturase or ⁇ 15-desaturase or d-15 desaturase or d15- Des or d15Des activity
- the carbon atoms C15-16 and / or C17-18 are each dehydrogenated by one hydrogen atom, forming a double bond between the two carbon atoms.
- delta-12 and delta-15 desaturase or ⁇ -12 and ⁇ -15 desaturase or spelled above
- delta-12 and delta-15 desaturase or ⁇ -12- and ⁇ 15-desaturase or as indicated above
- Activity refers to an enzyme having the enzymatic function of dehydrogenating C18 and / or C20 fatty acids attached to C-atoms 6-7, 8-9, 9-10 and / or 13-14 are dehydrogenated.
- the C atoms C12-13 and C15-16 and / or C17-18 are dehydrogenated by one hydrogen atom, forming a double bond between the two C atoms.
- omega 3-desaturase or ⁇ 3-desaturase or ⁇ 3-des or ⁇ 3Des or omega3 des or o3Des
- an enzyme having the enzymatic function refers to the dehydrogenation of C18, C20 and / or C22 fatty acids present at C-atoms 4-5, 5-6, 6-7, 8-9, 9-10 , 13-14 and / or 16-17 are dehydrogenated. In doing so, the C Atoms C15-16 and / or C17-18 and / or C19-20 dehydrogenated by one hydrogen atom, wherein a double bond between the two carbon atoms formed.
- polynucleotide sequences or polypeptide sequences according to the invention are preferably derived from the above-mentioned organisms.
- the aforementioned specific sequences may also be altered in view of the degenerate genetic code, of the altered polynucleotides still having polypeptides having an amino acid sequence according to one of SEQ ID NOS: 3, 6, 9, 12, 15, 18, 21, 24, 27, 92, 124, 127, 130, 133, 136, 144, 147, 150, 153, 156, or 158 having the aforementioned desaturase activities.
- polynucleotide also includes variants of the aforementioned specific polynucleotides. These may be homologous, orthologous or paralogue sequences. Such variants include nucleic acid sequences which have at least one base exchange, a base addition or a base deletion, wherein the variants are still intended to code a polypeptide having the aforementioned biological activity of the respective starting sequence. Variants include polynucleotides that can hybridize to the aforementioned polynucleotides, preferably under stringent conditions. Particularly preferred stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6.
- SSC sodium chloride / sodiumcitrate
- the temperature is different for example, under "standard hybridization conditions" depending on the type of nucleic acid between 42 0 C and 58 0 C in aqueous buffer with a concentration of 0.1 to 5 x SSC (pH 7.2). If organic solvent is present in the abovementioned buffer, for example 50% formamide, the temperature under standard conditions is approximately 42 0 C.
- the hybridization conditions for DNA: DNA hybrids are, for example, 0.1 x SSC and 2O 0 C to 45 0 C, preferably between 3O 0 C and 45 0 C.
- the hybridization conditions for DNA: RNA hybrids are, for example, 0.1 x SSC and 3O 0 C to 55 0 C, preferably between 45 0 C and 55 0 C.
- variants of the specific polynucleotides of the invention may also be provided by polymerase chain reaction (PCR) based methods.
- primers can first be derived from conserved sequences (eg sequences encoding functional domains in the polypeptide). conserveed sequences can be determined by sequence comparisons with polynucleotides encoding polypeptides of similar activity.
- DNA or cDNA from bacteria, fungi, plants or animals can be used.
- DNA fragments obtained by the PCR can be used to screen corresponding genomic or cDNA libraries to isolate, if necessary, the complete open reading frame of the polynucleotide and to determine by sequencing.
- Preferred variants include polynucleotides comprising a nucleic acid sequence comprising at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%. , at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% (or at any other percentage referred to herein) is identical to one of the aforementioned specific nucleic acid sequences and a polypeptide encoded with the respective biological activity.
- polynucleotides comprising nucleic acid sequences encoding a polypeptide having an amino acid sequence comprising at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%.
- the percentage of identical nucleotides or amino acids preferably refers to a sequence segment of at least 50% of the sequences to be compared, and more preferably over the entire length of the sequences to be compared.
- a variety of programs that implement algorithms for such comparisons are described in the prior art and are commercially available. In particular, reference is made to the algorithms of Needleman and Wunsch or Smith and Waterman, which provide particularly reliable results. These algorithms can preferably be implemented by the following programs: PiIeUp (J. Mol. Evolution., 25, 351-360, 1987, Higgins et al., CABIOS, 5 1989: 151-153), Gap and Bestfit (Needleman and Wunsch (J. Mol. Biol. 48: 443-453 (1970)) and Smith and Waterman (Adv.
- the percentage (%) of the sequence identity in the context of the present invention with the GAP program over the entire sequence with the following specified sizes is determined: Gap Weight: 50, Length Weight: 3, Average Match: 10,000 and Average Mismatch: 0.000 ,
- a polynucleotide which comprises only a fragment of the aforementioned nucleic acid sequences is also a polynucleotide according to the invention. The fragment is intended to encode a polypeptide which has the biological activity of the starting sequence or of the polypeptide encoded therefrom.
- Polypeptides encoded by such polynucleotides therefore comprise or consist of domains of the aforementioned specific polypeptides (parent polypeptides) which mediate biological activity.
- a fragment according to the invention preferably comprises at least 50, at least 100, at least 250 or at least 500 consecutive nucleotides of the aforementioned specific sequences or encodes an amino acid sequence comprising at least 20, at least 30, at least 50, at least 80, at least 100 or at least 150 consecutive amino acids one of the aforementioned specific amino acid sequences and mediates biological activity, preferably desaturase activity as described above.
- polynucleotide variants of the invention preferably have at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the respective biological activity of the polypeptide is encoded by the starting sequence.
- polypeptides which are encoded by the polynucleotides according to the invention can participate in the metabolism of compounds necessary for the formation of fatty acids, fatty acid esters such as diacylglycerides and / or triacylglycerides in an organism, preferably in a plant or plant cell, or in the transport of molecules via membranes in which Ci ⁇ -, C20- or C22-carbon chains in the fatty acid molecule having double bonds at least two, preferably three, four, five or six positions are meant.
- the polynucleotides of the invention either comprise or consist of the aforementioned specific nucleic acid sequences.
- the polynucleotides according to the invention may in principle also comprise further nucleotides. These may preferably be 3 ' or 5 ' untranslated regions of the genomic nucleic acid sequence. These are preferably of at least 100, 200 or 500 nucleotides at the 5 'terminus and at least 20, 50 or 100 nucleotides at the 3' terminus of the coding region.
- Other polynucleotides comprising additional nucleic acid sequences are those encoding fusion proteins. Such fusion proteins may code additional polypeptides or polypeptide portions in addition to the aforementioned polypeptides.
- the additional polypeptide or polypeptide portion may be other enzymes of lipid or fatty acid biosynthesis.
- polypeptides which can serve as markers for expression green, yellow, red, blue-fluorescent proteins, alkaline phosphatase, etc.
- tags as markers or aid for purification (eg FLAG tags , 6-histidine tags, MYC tags, etc.).
- Polynucleotide variants can be isolated from various natural or artificial sources. For example, they can be generated artificially by in vitro or in vivo mutagenesis. Homologs or orthologues of the specific sequences can be obtained from a wide variety of animals, plants or microorganisms. Preferably, they are obtained from algae.
- algae such as Isochrysis, Euglena or Crypthecodinium
- algae / diatoms such as Thalassiosira, Phaeodactylum or Thraustochytrium, Pythium, Moose such as Physcomitrella, preferably Physcomitrella patens or Ceratodon
- very particularly preferred are the algae of the genera Euglena or the diatoms from the class of Oomycota such the genera Pythium or Phytophthora or fungi such as Postia placenta or Microdochium nivale or from the Department of Zygomycota from the genera Rhizopus.
- the polynucleotides can also be obtained from plants, preferably from the family of Selaginellaceae, such as Selaginella moellendorffii, or from higher plants, such as the stimulaceae such as Aleuritia, Calendula stellata, Osteospermum spinescens or Osteospermum hyoseroides, microorganisms such as fungi such as Aspergillus, Thraustochytrium, Phytophthora, Entomophthora, Rhizopus, Mucor or Mortierella, bacteria such as Shewanella, cyanobacteria such as Synechococcus, yeasts or animals such as nematodes such as Caenorhabditis, mollusks, insects or fish.
- Selaginellaceae such as Selaginella moellendorffii
- the stimulaceae such as Aleuritia, Calendula stellata, Osteospermum spinescens
- the polynucleotide variants are also preferably derived from an animal of the vertebrate order.
- the polynucleotides are particularly preferably derived from the class of Vertebrata; Euteleostomi, Actinopterygii; Neopterygii; Teleostei; Euteleostei, Protacanthopterygii, Salmoniformes; Salmonidae or Oncorhynchus and, most preferably, from the order of Salmoniformes such as the family Salmonidae such as the genus Salmo, for example, from the genera and species Oncorhynchus mykiss, Trutta trutta or Salmo trutta fario.
- polynucleotides according to the invention can hereby be isolated by means of standard molecular biological techniques and the sequence information provided here. Also, by comparison algorithms, for example, a homologous sequence or homologous, conserved sequence regions at the DNA or amino acid level can be identified. These may be used as a hybridization probe as well as standard hybridization techniques (such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., CoId Spring Harbor Laboratory, ColD Spring Harbor Laboratory Press, ColD Spring Harbor, NY, 1989) Isolation of other useful in the process of nucleic acid sequences can be used.
- polynucleotides or fragments thereof can be isolated by polymerase chain reaction (PCR) using oligonucleotide primers based on this sequence or portions thereof (eg, a nucleic acid molecule comprising the entire sequence or a portion thereof can be polymerase chain-reaction utilized isolated from oligonucleotide primers prepared on the basis of this same sequence).
- PCR polymerase chain reaction
- mRNA can be isolated from cells (eg, by the guanidinium thiocyanate extraction method of Chirgwin et al., (1979) Biochemistry 18: 5294-5299) and cDNA by reverse transcriptase (eg, Moloney MLV reverse transcriptase, available from Gibco / BRL, Bethesda, MD, or AMV Reverse Transcriptase, available from Seikagaku America, Inc., St. Russia, FL).
- reverse transcriptase eg, Moloney MLV reverse transcriptase, available from Gibco / BRL, Bethesda, MD, or AMV Reverse Transcriptase, available from Seikagaku America, Inc., St. Russia, FL.
- Synthetic oligonucleotide primers for polymerase chain reaction amplification can be prepared on the basis of the polynucleotide and amino acid sequences shown in SEQ ID Nos. (SEQ ID NO: 1).
- a nucleic acid of the invention may be amplified using cDNA or alternatively genomic DNA as a template and suitable oligonucleotide primers according to standard PCR amplification techniques.
- the thus amplified nucleic acid can be cloned into a suitable vector and characterized by DNA sequence analysis.
- Oligonucleotides corresponding to a desaturase nucleotide sequence may be replaced by standard Synthesis method, for example, with an automatic DNA synthesizer manufactured.
- the polynucleotides of the invention may be provided either as isolated polynucleotides (ie, isolated from their natural origin, eg, the genomic locus) or in genetically altered form (ie, the polynucleotides may also be present at their natural genetic locus, but must then be genetically engineered).
- An isolated polynucleotide preferably comprises less than 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleic acid sequence naturally present in its vicinity.
- the polynucleotide according to the invention may be present as a single-stranded or double-stranded nucleic acid molecule and be genomic DNA, cDNA or RNA.
- the polynucleotide of the invention consists of RNA or DNA.
- the polynucleotides of the invention comprise all orientations of the sequences shown in the SEQ ID Nos., I. also complementary strands and reverse or reverse-complementary orientations.
- the term also includes chemically modified nucleic acids, such as the naturally occurring methylated DNA molecules, or artificial nucleic acids, e.g. biotinylated nucleic acids.
- the invention also includes oligonucleotides of at least 15 bp, preferably at least 20 bp, at least 25 bp, at least 30 bp, at least 35 bp, or at least 50 bp, which can specifically hybridize with one of the abovementioned polynucleotides under stringent conditions.
- the oliguncleotides may consist of DNA or RNA or both.
- Such oligonucleotides can be used as primers for PCR, as expression-inhibiting, antisense oligonucleotides, for RNA interference (RNAi) or for chimeric or genomic approaches.
- RNAi RNA interference
- RNAi methods are described, for example, in Fire et al., Nature (1998) 391: 806-811; Fire, Trends Genet. 15, 358-363 (1999); Sharp, RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond et al. Nature Rev. Genet. 2,11,10-1,119 (2001); Tuschl, Chem. Biochem. 2, 239-245 (2001); Hamilton et al., Science 286, 950-952 (1999); Hammond et al., Nature 404, 293-296 (2000); Zamore et al., Cell 101, 25-33 (2000); Bernstein et al., Nature 409, 363-366 (2001); Elbashir et al. Genes Dev.
- the polynucleotides according to the invention can be used particularly effectively for the recombinant production of polyunsaturated fatty acids in host cells and transgenic organisms.
- the polypeptides encoded by the polynucleotides of the invention with ⁇ -12-desaturase, ⁇ 15-desaturase, ⁇ -12 and ⁇ -15-desaturase or omega-3-desaturase activity Ci ⁇ -, C20- and C22-fatty acids with one or two , three, four or five double bonds and preferably polyunsaturated C18 fatty acids having one, two or three double bonds such as C18: 1 ⁇ 9 , C18: 2 A9 12 or C18: 3 ⁇ 6 . 9 .
- polyunsaturated C2o fatty acids with three or four double bonds such as C20: 3 ⁇ 8 11 14 , C20: 4 A5 8 11 14 or C20: 4 A8 11 14 17 or polyunsaturated C22 fatty acids with four or five double bonds such as C22 : 4 ⁇ 7 10 13 16 or C22: 5 Convert ⁇ 7 ' 10 ' 13 ' 16 ' 19 .
- the polynucleotide and amino acid sequences according to the invention particularly preferably lead to an increase in the 18: 2 ⁇ 9,12 or 18: 3 ⁇ 9,12,15 fatty acids.
- FIG. 1 illustrates where the desaturases according to the invention attack the biosynthesis of long-chain polyunsaturated fatty acids or how they can be used to produce these fatty acids.
- a ⁇ 12-desaturase, ⁇ 15-desaturase, ⁇ 12- and ⁇ -15-desaturase, or omega-3-desaturase according to the invention, alone or in a suitable combination (for example a ⁇ 12-desaturase and a ⁇ 15-desaturase ), together with d ⁇ Des (Pir) and / or d6Des (Ot), d6Elo (Pp), d5Des (Tc), and ⁇ 3Des (Pi) are used to make EPA.
- a ⁇ -12-desaturase, ⁇ 15-desaturase, ⁇ -12- and ⁇ -15-desaturase, or omega-3-desaturase can be used to make docosahexaenoic acid.
- the fatty acids are preferably desaturated in phospholipids or CoA fatty acid esters, advantageously in the CoA fatty acid esters.
- the unsaturated fatty acids prepared by means of the polynucleotides according to the invention can then be formulated as oil, lipid and fatty acid compositions and used accordingly.
- the present invention further relates to a vector comprising the polynucleotide of the invention.
- vector denotes a nucleic acid molecule which can transport another nucleic acid molecule, such as the polynucleotides according to the invention, to which it is bound.
- plasmid that represents a circular double-stranded DNA loop into which additional DNA segments can be ligated.
- viral vector Another type of vector is a viral vector, where additional DNA segments can be ligated into the viral genome.
- Certain vectors may autonomously replicate in a host cell into which they have been introduced (eg bacterial vectors of bacterial origin of replication).
- vectors are advantageously integrated into the genome of a host cell upon introduction into the host cell and thereby replicated together with the host genome.
- certain vectors may direct the expression of genes to which they are operably linked. These vectors are also referred to herein as expression vectors.
- expression vectors suitable for recombinant DNA techniques are in the form of plasmids.
- plasmid and vector can be used interchangeably since the plasmid is the most commonly used vector form.
- the invention is intended to encompass these other forms of expression vectors, such as viral vectors that perform similar functions.
- vector is also intended to mean other vectors which are known to the person skilled in the art, such as phages,
- Viruses such as SV40, CMV, TMV, transposons, IS elements, phasmids, phagemids, cosmids, linear or circular DNA, artificial chromosomes.
- the term also includes constructs for targeted, i. homologous recombination, or heterologous insertion of polynucleotides.
- Vectors can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
- transformation and “transfection”, conjugation and transduction are intended to encompass a variety of methods known in the art for introducing foreign nucleic acid (eg DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE- Dextran-mediated transfection, lipofection, natural competence, chemically mediated transfer, electroporation or particle bombardment.
- Suitable methods for transformation or transfection of host cells, including plant cells can be found in Sambrook et al.
- Suitable cloning vectors are well known to those skilled in the art. These include, in particular, vectors which can be replicated in microbial systems, ie in particular vectors which ensure efficient cloning in yeasts or fungi, and which enable stable transformation of plants.
- various suitable for T-DNA-mediated transformation binary and co-integrated vector systems.
- Such vector systems are generally characterized in that they contain at least the vir genes required for the Agrobacterium-mediated transformation as well as the T-DNA limiting sequences (T-DNA border).
- these vector systems also include other cis-regulatory regions, such as promoters and terminators and / or selection markers, with which appropriately transformed organisms can be identified.
- binary systems are based on at least two vectors, one of them vir genes, but no T-DNA and a second T-DNA, but does not carry a vir gene.
- these binary vectors include vectors of the series pBIB-HYG, pPZP, pBecks, pGreen. Bin19, pBI101, pBinAR, pGPTV and pCAMBIA are preferably used according to the invention.
- the vectors with the inserted polynucleotides according to the invention can be stably propagated in microorganisms, in particular Escherichia coli and Agrobacterium tumefaciens, under selective conditions and enable a transfer of heterologous DNA into plants or microorganisms.
- the polynucleotides according to the invention can be introduced into organisms such as microorganisms or plants and thus to Plant transformation can be used.
- the vector is an expression vector.
- the polynucleotide is in operative (i.e., functional) connection to an expression control sequence.
- the expression control sequence together with the polynucleotide and optionally further sequence elements of the vector is also referred to as expression cassette.
- the expression coercive sequence ensures that the polynucleotide can be expressed in a host cell after transformation or transfection.
- the expression control sequence to be used preferably contains cis-regulatory elements such as promoter and / or enhancer nucleic acid sequences, which are recognized by the transcription machinery of the host cells.
- the term also includes other expression control elements, e.g.
- RNA stabilizing sequences Polyadenylation signals and RNA stabilizing sequences. These regulatory sequences are described, for example, in Goeddel: Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990), or see: Gruber and Crosby, in: Methods in Plant Molecular Biology and Biotechnolgy, CRC Press, Boca Raton , Florida, Ed .: Glick and Thompson, Chapter 7, 89-108, including references therein.
- Expression control sequences include those that direct the constitutive expression of a nucleotide sequence in many types of host cells and those that direct the direct expression of the nucleotide sequence only in certain host cells under certain conditions.
- the design of the expression vector may depend on factors such as the selection of the host cell to be transformed, the level of expression of the desired protein, etc.
- the polynucleotides of the invention may be in one or more copies in the expression cassette or the expression vector according to the invention are present (eg in the form of several expression cassettes).
- the regulatory sequences or factors can, as described above, preferably positively influence the gene expression of the introduced genes and thereby increase them.
- enhancement of the regulatory elements can advantageously be done at the transcriptional level by using strong transcription signals such as promoters and / or enhancers.
- an enhancement of the translation is possible by, for example, the stability of the mRNA is improved.
- control sequences in the sense of the present invention are translation terminators at the 3 'end of the polynucleotides to be translated.
- the OCSI terminator can be used here.
- a different terminator sequence should be used for each polynucleotide to be expressed.
- Preferred expression control sequences or regulatory sequences are present in promoters, such as the cos, tac, trp, tet, trp-tet, lpp, lac, lpp-lac, laclq, T7, T5, T3 , gal, trc, ara, SP6, ⁇ -PR or ⁇ -PL promoter and are advantageously used in Gram-negative bacteria.
- promoters amy and SPO2 in the yeast or fungal promoters ADC1, MFa, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH or in the plant promoters CaMV / 35S [Franck et al., Cell 21 (1980) 285-294], PRP1 [Ward et al., Plant. Biol. 22 (1993)], SSU, OCS, Iib4, usp, STLS1, B33, nos or in the ubiquitin or phaseolin promoter.
- inducible promoters such as those described in EP-AO 388 186 (benzylsulfonamide-inducible), Plant J.
- Suitable plant promoters are the cytosolic FBPase promoter or potato ST-LSI promoter (Stockhaus et al., EMBO J. 8, 1989, 2445), the phosphoribosylprophosphate amidotransferase enzyme.
- Glycine max (Genbank accession No. U87999) promoter or the nodular-specific promoter described in EP-A-0 249 676.
- Particularly advantageous promoters are promoters which allow the expression in tissues that at the Fatty acid biosynthesis are involved.
- Very particular advantage are seed-specific promoters, such as the USP promoter but also other promoters such as the LeB4, DC3, phaseolin or napin promoter.
- Further particularly advantageous promoters are seed-specific promoters which can be used for monocotyledonous or dicotyledonous plants and in US Pat. No. 5,608,152 (rapeseed napin promoter), WO 98/45461 (oleosin promoter from Arobidopsis), US Pat. No.
- the polynucleotides of the present invention should preferably be seed-specifically expressed in oilseeds.
- seed-specific promoters can be used, or such promoters that are active in the embryo and / or in the endosperm.
- seed-specific promoters can be isolated from both dicotolydone and monocotolydone plants.
- Plant gene expression can also be facilitated by a chemically inducible promoter (see review in Gatz 1997, Annu Rev. Plant Physiol Plant Mol. Biol., 48: 89-108).
- Chemically inducible promoters are particularly useful when it is desired that gene expression be in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter (WO 95/19443), a tetracycline-inducible promoter (Gatz et al. (1992) Plant J. 2, 397-404) and an ethanol-inducible promoter.
- each of the polynucleotides according to the invention should be expressed under the control of their own preferably a different promoter, since repetitive sequence motifs can lead to instability of the T-DNA or to recombination events.
- the expression cassette is advantageously constructed in such a way that a promoter follows a suitable interface for insertion of the nucleic acid to be expressed (advantageously in a polylinker), and optionally subsequently a terminator lies behind the polylinker.
- This sequence is repeated several times, preferably three, four or five times, so that up to five genes can be brought together in one construct and thus introduced into the transgenic plant for expression.
- the sequence is repeated up to three times.
- each nucleic acid sequence has its own promoter and optionally its own terminator.
- Such advantageous constructs are disclosed for example in DE 10102337 or DE 10102338.
- the insertion site or the sequence of the inserted nucleic acids in the expression cassette is not of crucial importance, ie a nucleic acid sequence can be at the first or last position be inserted in the cassette, without thereby the expression is significantly affected.
- the recombinant expression vectors used may be designed for expression in prokaryotic or eukaryotic cells. This is advantageous because intermediate steps of the vector construction are often carried out in microorganisms for the sake of simplicity.
- Suitable host cells are further discussed in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
- the recombinant expression vector may alternatively be transcribed and translated in vitro using, for example, T7 promoter regulatory sequences and T7 polymerase.
- the expression of proteins in prokaryotes is usually carried out with vectors containing constitutive or inducible promoters which direct the expression of fusion or non-fusion proteins.
- Typical fusion expression vectors include pGEX (Pharmacia Biotech Ine, Smith, DB, and Johnson, KS (1988) Gene 67: 31-40), pMAL (New England Biolabs, Beverly, MA), and pRIT5 (Pharmacia, Piscataway, NJ). in which glutathione-S-transferase (GST), maltose E-binding protein or protein A is fused to the recombinant target protein.
- GST glutathione-S-transferase
- suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al.
- Target gene expression from the pTrc vector is based on transcription by host RNA polymerase from a hybrid trp-lac fusion promoter.
- Target gene expression from the pET lld vector is based on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl).
- This viral polymerase is provided by the host strains BL21 (DE3) or HMS174 (DE3) from a resident ⁇ prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
- Other suitable vectors in prokaryotic organisms are known to those skilled in the art, these vectors are, for example, in E.
- the pBR series such as pBR322
- the pUC series such as pUC18 or pUC19
- the M113mp series such as pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200,
- the expression vector is a yeast expression vector.
- yeast expression vectors for expression in the yeast S. cerevisiae include pYeDesaturasecl (Baldari et al. (1987) Embo J. 6: 229-234), pMFa (Kurjan and Herskowitz (1982).
- Vectors and methods for constructing vectors suitable for use in other fungi, such as filamentous fungi include those described in detail in: van den Hondel, CAMJJ, & Punt, PJ (1991) "Gene transfer Systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, JF Peberdy et al., Eds., pp. 1-28, Cambridge University Press: Cambridge, or in: More Gene Manipulations in Fungi [JW Bennet & LL Lasure,
- yeast vectors are, for example, pAG-1, YEp6, YEp13 or pEMBLYe23.
- polynucleotides of the present invention may also be expressed in insect cells using baculovirus expression vectors.
- Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) Mol. Cell Biol. 3: 2156-2165) and the pVL series. Series (Lucklow and Summers (1989) Virology 170: 31-39).
- Preferred plant expression vectors include those described in detail in: Becker, D., Kemper, E., Schell, J., and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border "Plant Mol. Biol. 20: 1 195-1197; and Bevan, MW (1984) Binary Agrobacterium vectors for Plant Transformation, Nucl. Acids Res. 12: 871 1 -8721; Vectors for Gene Transfer to Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds .: Kung and R. Wu, Academic Press, 1993, pp. 15-38.
- a plant expression cassette preferably contains expression control sequences which can direct gene expression in plant cells and are operatively linked so that each sequence can fulfill its function, such as termination of transcription, for example, polyadenylation signals.
- Preferred polyadenylation signals are those derived from Agrobacterium tumefaciens T-DNA, such as the gene 3 of the Ti plasmid pTiACH ⁇ known as octopine synthase (Gielen et al., EMBO J. 3 (1984) 835ff.) Or functional equivalents thereof, but also all other terminators functionally active in plants are suitable.
- a plant expression cassette preferably contains other operably linked sequences, such as translation enhancers, for example the overdrive sequence containing the 5'-untranslated tobacco mosaic virus leader sequence encoding the protein / RNA Ratio increases (GaIMe et al., 1987, Nucl. Acids Research 15: 8693-871 1).
- Plant gene expression, as described above, must be operably linked to a suitable promoter that performs gene expression in a timely, cell or tissue-specific manner.
- Useful promoters are constitutive promoters (Benfey et al., EMBO J.
- the nucleus in the vacuole, the nucleus, all types of plastids, such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondes, the endoplasmic reticulum, oil bodies, peroxisomes and other compartments of plant cells.
- plastids such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondes, the endoplasmic reticulum, oil bodies, peroxisomes and other compartments of plant cells.
- Plant gene expression can also be facilitated by a chemically inducible promoter as described above (see review in Gatz 1997, Annu Rev. Plant Physiol Plant Mol. Biol., 48: 89-108).
- Chemically inducible promoters are particularly useful when it is desired that gene expression be in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter (WO 95/19443), a tetracycline-inducible promoter (Gatz et al. (1992) Plant J. 2, 397-404) and an ethanol-inducible promoter.
- Promoters which react to biotic or abiotic stress conditions are also suitable promoters, for example the pathogen-induced PRP1 gene promoter (Ward et al., Plant Mol. Biol. 22 (1993) 361-366), the heat-inducible hsp80 promoter Tomato (US Pat. No. 5,187,267), the potato-inducing alpha-amylase promoter (WO 96/12814) or the wound-inducible pinII promoter (EP-A-0 375 091).
- the pathogen-induced PRP1 gene promoter Ward et al., Plant Mol. Biol. 22 (1993) 361-366
- the heat-inducible hsp80 promoter Tomato US Pat. No. 5,187,267
- the potato-inducing alpha-amylase promoter WO 96/1281
- the wound-inducible pinII promoter EP-A-0 375 091
- promoters which induce gene expression in tissues and organs in which the fatty acid, lipid and oil biosynthesis take place are preferred in sperm cells such as the cells of the endosperm and the developing embryo.
- Suitable promoters are the rapeseed napkin promoter (US 5,608,152), the Vicia faba USP promoter (Baeumlein et al., Mol Gen Genet, 1991, 225 (3): 459-67), the Arabidopsis oleosin promoter (US Pat.
- phaseolin promoter from Phaseolus vulgaris (US 5,504,200), the Brassica Bce4 promoter (WO 91/13980) or the legumin B4 promoter (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2): 233-9) as well as promoters expressing seed-specific expression in monocotyledonous plants such as maize, Barley, wheat, rye, rice, etc. bring.
- Suitable noteworthy promoters are the lpt2 or lpt1 gene promoter from barley (WO 95/15389 and WO 95/23230) or those described in WO 99/16890 (promoters from the barley hordein gene, the rice glutelin gene , the rice-oryzin gene, the rice prolamin gene, the wheat gliadin gene, the wheat glutelin gene, the maize zein gene, the oat glutelin gene, the sorghum casirin gene, the Rye secaline gene). Also particularly suitable are promoters which induce plastid-specific expression, since plastids are the compartment in which the precursors and some end products of lipid biosynthesis are synthesized. Suitable promoters, such as the viral RNA polymerase promoter, are described in WO 95/16783 and WO 97/06250, and the Arabidopsis clpP promoter described in WO 99/46394.
- the expression vector can, as described above, in addition to the polynucleotides of the invention also include other genes to be introduced into the organisms. It is possible and preferred to introduce into the host organisms regulatory genes, such as genes for inducers, repressors or enzymes, which intervene by their enzyme activity in the regulation of one or more genes of a biosynthetic pathway, and to express therein. These genes may be of heterologous or homologous origin. Heterologous genes or polynucleotides are derived from a parent organism distinct from the target organism into which the genes or polynucleotides are to be introduced. For homologous genes or polynucleotides, the target organism and the parent organism are the same.
- the vector comprises at least another polynucleotide encoding another enzyme involved in the biosynthesis of lipids or fatty acids.
- the invention also relates to a host cell which comprises the polynucleotide or the vector according to the invention.
- Host cells in the sense of the present invention can in principle be all eukaryotic or prokaryotic cells. They may be primary cells from animals, plants or multicellular microorganisms, e.g. from those mentioned elsewhere in the description. Furthermore, the term also includes cell lines that can be obtained from these organisms.
- host cells according to the invention may also be unicellular microorganisms, for example bacteria or fungi.
- Particularly preferred microorganisms are fungi selected from the family of Chaetomiaceae, Choanephoraceae, Cryptococcaceae, Cunninghamellaceae, Demetiaceae, Hydnangiaceae (genus Laccaria), Moniliaceae, Mortierellaceae, Mucoraceae, Pythiaceae, Sacharomycesaceae, Saprolegniaceae, Schizosacharomycetaceae, Sodariaceae or Tuberculariaceae.
- Choanephoraceae as the genera Blakeslea, Choanephora eg the genera and species Blakeslea trispora, Choanephora cueurbitarum, Choanephora infundibulifera var.
- Mortierellaceae such as the genus Mortierella eg the genera and species Mortierella isabellina, Mortierella polycephala, Mortierella ramanniana, Mortierella vinacea, Mortierella zonata, the family of Mucorales as the genera and Species Rhizopus oryzae, Rhizopus stolonifer, Fusarium grami-nium, Pythiaceae such as the genera Phytium, Phytophthora eg the genera and species Pythium debaryanum, Pythium intermedium, Pythium irregular, Pythium megalacanthum, Pythium paroecandrum, Pythium sylvaticum, Pythium ultimum, Phytophthora cactorum, Phytophthora cinnamomi , Phytophthora citricola, Phyt
- Thraustochytriaceae such as the genera Althornia, Aplanochytrium, Japonochytrium, Schizochytri to, Thraustochytrium aggregatum such as Schizochytrium, Schizochytrium limacinum, Schizochytrium mangrove vei, Schizochytrium minutum, Schizochytrium octosporum, Thraustochytrium aggregatum, Thraustochytrium amoeboideum, antacticum Thraustochytrium, Thraustochytrium arudimentale, Thraustochytrium aureum, Thraustochytrium benthicola, Thraustochytrium globosum, Thraustochytrium indicum, Thraustochytrium kerguelense , Thraustochytrium kinnei, Thraustochytrium motiveum,
- Thraustochytrium multirudimentale Thraustochytrium pachydermum, Thraustochytrium proliferum, Thraustochytrium roseum, Thraustochytrium rossii, Thraustochytrium striatum or Thraustochytrium visurgense.
- bacteria selected from the group of the families Bacillaceae, Enterobacteriacae or Rhizobiaceae Particular preference is given to the following bacteria selected from the group: Bacillaceae such as the genus Bacillus eg the genera and species Bacillus acidocaldarius, Bacillus acidoterrestris, Bacillus alcalophilus, Bacillus amyloliquefiens, Bacillus amylolyticus, Bacillus brevis, Bacillus cereus, Bacillus circulans, Bacillus coagulans , Bacillus sphaericus subsp.
- Bacillaceae such as the genus Bacillus eg the genera and species Bacillus acidocaldarius, Bacillus acidoterrestris, Bacillus alcalophilus, Bacillus amyloliquefiens, Bacillus amylolyticus, Bacillus brevis, Bacillus cereus, Bacillus circulans, Bacillus coagulans , Bacillus
- Enterobacteriacae such as the genera Citrobacter, Edwardiella, Enterobacter, Erwinia, Escherichia, Klebsiella, Salmonella or Serratia z.
- Enterobacteriacae such as the genera Citrobacter, Edwardiella, Enterobacter, Erwinia, Escherichia, Klebsiella, Salmonella or Serratia z.
- B the genera and species Citrobacter amalonaticus, Citrobacter diversus, Citrobacter freu ndii, Citrobacter genomospecies, Citrobacter gillenii, Citrobacter intermedium, Citrobacter koseri, Citrobacter murliniae, Citrobacter sp., Edwardsiella hoshinae, Edwardsiella ictaluri, Edwardsiella tarda, Erwinia alni, Erwinia amylovora, Erwinia ananatis, Erwinia aphidicola
- Salmonella daressalaam Salmonella enterica subsp. houtenae, Salmonella enterica subsp. salamae, Salmonella enteritidis, Salmonella gallinarum, Salmonella heidelberg, Salmonella panama, Salmonella senftenberg, Salmonella typhimurium, Serratia entomophila, Serratia ficaria, Serratia fonticola, Serratia grimesii, Serratia liquefaciens, Serratia marcescens, Serratia marcescens subsp.
- Rhizobiaceae such as the genera Agrobacterium, Carbophilus, Chelatobacter, Ensifer, Rhizobium, Sinorhizobium eg the genera and species Agrobacterium atlanticum, Agrobacterium ferrugineum, Agrobacterium gelatino- vorum, Agrobacterium larrymoorei, Agrobacterium meteori, Agrobacterium radiobacter, Agrobacterium rhizogenes, Agrobacterium rubi, Agrobacterium stellulatum , Agrobacterium tumefaciens, Agrobacterium vitis, Carbophilus carboxidus, Chelatobacter hein
- Useful host cells are also mentioned in: Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
- Useful expression strains e.g. those which have a lower protease activity are described in: Gottesman, S., Gene Expression Technology:
- the host cell according to the invention preferably additionally comprises at least one further enzyme, which is involved in the biosynthesis of lipids or fatty acids.
- Preferred enzymes are already mentioned elsewhere in the description.
- the enzyme may be endogenous to the host cell, i.
- the host cell already naturally expresses a gene that codes for a corresponding enzyme.
- a heterologous polynucleotide may be introduced into the host cell encoding the enzyme. Suitable methods and measures for the expression of a heterologous polynucleotide are known in the art and described herein in connection with the poly nucleotides, vectors and host cells according to the invention.
- the invention also relates to a process for the preparation of a polypeptide having desaturase activity, comprising the steps:
- the polypeptide can be obtained or isolated by all common methods for protein purification.
- the methods include, for example, affinity chromatography, molecular sieve chromatography, high pressure liquid chromatography or else protein precipitation optionally with specific antibodies.
- the method need not necessarily provide a pure preparation of the polypeptide.
- polypeptide which is encoded by the polynucleotide according to the invention or which is obtainable by the abovementioned method according to the invention.
- polypeptide refers to both a substantially pure polypeptide and a polypeptide preparation that contains other components or contaminants.
- the term is also used for fusion proteins or protein aggregates which comprise the polypeptide according to the invention and additionally further components.
- the term also refers to chemically modified polypeptides. Chemical modifications in this context include artificial modifications or naturally occurring modifications, eg, post-translational modifications such as phosphorylation, myristylation, glycosylation, etc.
- polypeptide, peptide, or protein are interchangeable and will be used accordingly in the description and in the art.
- the polypeptides according to the invention have the abovementioned biological activities, ie desaturase activities, and can influence the biosynthesis of polyunsaturated fatty acids (PUFAs), preferably the long-chain PUFAs (LCPU-FAs), as described herein.
- PUFAs polyunsaturated fatty acids
- LCPU-FAs long-chain PUFAs
- the invention also encompasses an antibody which specifically recognizes the polypeptide according to the invention.
- Antibodies to the polypeptide of the invention can be with known antibodies
- Suitable epitopes may be determined by known antigenicity determination algorithms based on the amino acid sequences provided herein of the polypeptides of the invention.
- the corresponding polypeptides or fragments can then be synthesized or recombinantly recovered.
- suitable animals preferably mammals e.g. Rabbits, rats or mice
- the antibodies can then be recovered from the serum by known methods.
- monoclonal antibodies or antibody fragments may be provided by known methods; see, e.g. Harlow and Lane
- the antibodies are preferably monoclonal or polyclonal antibodies, "single-chain” antibodies or chimeric antibodies and fragments thereof such as Fab, Fv or scFv. Further antibodies within the meaning of the invention are bispecific antibodies, synthetic antibodies or their chemically modified derivatives.
- the antibodies of the invention specifically recognize the polypeptides of the invention, i. they do not cross-react significantly with other proteins.
- an antibody of the invention that specifically binds a ⁇ 12-desaturase does not react with a ⁇ 6-desaturase. This can be tested by methods known in the art.
- the antibodies can be used, for example, for detection reactions, for immunoprecipitation, for immunohistochemistry or for protein purification (for example affinity chromatography).
- the invention further relates to a transgenic, non-human organism comprising the polynucleotide, the vector or the host cell of the present invention.
- the transgenic, non-human organism is an animal, a plant or a multicellular microorganism.
- transgenic is to be understood as meaning that a heterologous polynucleotide, ie a polynucleotide which does not naturally occur in the particular organism, is introduced into the organism, which can be achieved either by random insertion of the polynucleotide or by homologous recombination Methods of introducing polynucleotides or vectors for random insertion or homologous recombination are well known in the art and are described in more detail below: Host cells containing the polynucleotide or vector may also be incorporated into a polynucleotide or vector In such an organism is then but a chimeric organism in which only the cells that are different from the derived cells are transgenic, ie include the heterologous polynucleotide.
- the transgenic, non-human organisms are oil-producing organisms, that is, those used for the production of oils, for example, fungi such as Rhizopus or Thraustochytrium, algae such as Euglena, Nephroselmis, Pseudoscourfielda, Prasinococcus, Scherffelia, Tetraselmis, Mantoniella. Ostreococcus, Crypthecodinium, Phaeodactylum, Diatoms such as Pytium or Phytophthora or plants.
- all plants can be used as transgenic plants, i. both dicotyledonous and monocotyledonous plants.
- they are oilseed crops containing high levels of lipid compounds such as peanut, rapeseed, canola, sunflower, safflower (Carthamus tinctoria), poppy, mustard, hemp, castor, olive, sesame, calendula, punica, evening primrose, mullein, thistle , Wild roses, hazelnut, almond, macadamia, avocado, bay leaf, pumpkin, flax, soy, pistachio, borage, trees (oil palm, coconut or walnut) or crops such as corn, wheat, rye, oats, triticale, rice, barley, cotton , Cassava, pepper, tagetes, solanaceae plants such as potato, tobacco, aubergine and tomato, Vicia species, pea, alfalfa or bush plants (coffee, cocoa, tea), Salix species and perennial grass
- Preferred plants according to the invention are oil crop plants, such as peanut, rapeseed, canola, sunflower, safflower, poppy, mustard, hemp, castor, olive, calendula, punica, evening primrose, pumpkin, flax, soy, borage, trees (oil palm, coconut).
- Particularly preferred are C18: 2 and / or C18: 3 fatty acid rich plants such as sunflower, safflower, tobacco, mullein, sesame, cotton, pumpkin, poppy, evening primrose, walnut, flax, hemp, thistle or safflower.
- plants such as safflower, sunflower, poppy, evening primrose, walnut, flax or hemp. In principle, however, all plants are eligible, which are able to synthesize fatty acids as all dicots or monocots
- Plants, algae or mosses are selected from the group of the plant families Adelotheciaceae, Anacardiaceae, Asteraceae, Apiaceae, Betulaceae, Boraginaceae, Brassicaceae, Bromeliaceae, Caricaceae, Canna- baceae, Convolvulaceae, Chenopodiaceae, Crypthecodiniaceae, Cucurbitaceae, Ditrichaceae, Elaeagnaceae, Ericaceae, Euphorbiaceae, Fabaceae, Geraniaceae, Gramineae, Juglandaceae, Lauraceae, Leguminosae, Linaceae, Prasinophyceae, or vegetables or ornamentals such as Tagetes.
- Adelotheciaceae Anacardiaceae, Asteraceae, Apiaceae, Betulaceae, Boraginaceae, Brassicaceae, Bromeliaceae, Caricaceae, Canna-
- Adelotheciaceae such as the genera Physcomitrella eg the genus and species Physcomitrella patens
- Anacardiaceae such as the genera Pistacia, Mangifera, Anacardium eg the genus and species Pistacia vera [pistachio], Mangifer indica [ Mango] or Anacardium occidentale [Cashew]
- Asteraceae such as the genera Calendula, Carthamus, Centaurea, Cichorium, Cynara, Helianthus, Lactuca, Locusta, Tagetes, Valeriana eg the genus and species Calendula officinalis [Gardening Marigold], Carthamus tinctorius [Coloring thistle, safflower], Centaurea cyanus [cornflower], Cichorium intybus [chicory], Cynara scolymus [Artichoke], Helianthus annus [sunflower],
- Elaeagnaceae such as the genus Elaeagnus eg the genus and species Olea europaea [Olive]
- Ericaceae as the genus Kalmia eg the genera and species Kalmia latifolia, Kalmia angustifolia, Kalmia microphylla,
- Physcomitrium eurystomum Physcomitrium flexifolium, Physcomitrium hookeri, Physcomitrium hookeri var. Serratum, Physcomitrium immersum, Physcomitrium kellermanii, Physcomitrium megalocarpum, Physcomitrium pyriforme, Physcomitrium pyriforme var.
- lewisii for example, the genera and species Linum usitatissimum , Linum pratense or Linum trigynum [flax], Lythrarieae as the genus Punica eg the genus and Art Punica granatum [pomegranate], Malvaceae as the genus Gossypium eg the genera and species Gossypium hirsutum, Gossypium arboreum, Gossypium barbadense, Gossypium herbaceum or Gossypium thurberi [Cotton], Marchantiaceae as the genus Marchantia eg the genera and species Marchantia berteroana, Marchantia foliacea, Marchantia macropora, Musaceae as the genus Musa eg the genera and species Musa nana, Musa acuminata, Musa paradisiaca, Musa spp.
- [Cayenne pepper] such as the genera Hordeum, Seeale, Avena, Sorghum, Andropogon, Holcus, Panicum, Oryza, Zea (maize), Triticum eg the genera and species Hordeum vulgare, Hordeum jubatum, Hordeum murinum, Hordeum secalinum, Hordeum distichon Hordeum aegiceras, Hordeum hexastichon, Hordeum hexa sting, Hordeum irregular, Hordeum sativum, Hordeum secalinum [barley], Seeale cereale [rye], Avena sativa, Avena fatua, Avena byzantina, Avena fatua var.
- Glabriusculum Capsicum frutenscens [pepper], capsicum annuum [paprika], nicotiana tabacum, nicotiana alata, nicotiana attenuata, nicotiana glauca, nicotiana langsdorffii, nicotiana obtusifolia, nicotiana quadrivalvis, nicotiana repdana, nicotiana rustica, nicotiana sylvestris [tobacco], solanum tuberosum [potato], Solanum melongena [aubergine] Lycopersicon esculentum, Lycopersicon lycopersicum., Lycopersicon pyriforme, Solanum integrifolium or Solanum lycopersicum [tomato], Sterculiaceae such as the genus Theobroma eg the genus and species Theobroma cacao [cocoa
- Multicellular microorganisms that can be used as transgenic non-human organisms are preferably protists or diatoms selected from the group of the family Dinophyceae, Turaniellidae or Oxytrichidae such as the genera and species: Crypthecodinium cohnii, Phaeodactylum tricornutum, Stylonychia mytilus, Stylonychia pustulata, Stylonychia putrina , Stylonychia notophora, Stylonychia sp., Colpidium campylum or Colpidium sp.
- protists or diatoms selected from the group of the family Dinophyceae, Turaniellidae or Oxytrichidae such as the genera and species: Crypthecodinium cohnii, Phaeodactylum tricornutum, Stylonychia mytilus, Stylonychia pustulata, Stylonychia putrina
- the invention further relates to a process for producing a substance having the structure shown in the following general formula I.
- R 1 hydroxyl, coenzyme A (thioester), lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysodiphosphatidylglycerol, lysophosphatidylserine, lysophosphatidylinositol, sphingolase or a radical of the formula II
- R 2 hydrogen, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysodiphosphatidylglycerol, lysophosphatidylserine, lysophosphatidylinositol or saturated or unsaturated C 2 -C 4 -alkylcarbonyl,
- R 3 hydrogen, saturated or unsaturated C 2 -C 4 -alkylcarbonyl, or R 2 and R 3 are, independently of one another, a radical of the formula Ia:
- the method comprises cultivating (i) a host cell according to the invention or (ii) a transgenic non-human organism according to the invention under conditions which allow the biosynthesis of the substance.
- the aforementioned substance is provided in an amount of at least 1% by weight based on the total content of the lipids in the host cell or the transgenic organism.
- R 1 in general formula I denotes hydroxyl, coenzyme A (thioester), lysophosphatidylcholine, lyso-phosphatidylethanolamine, lyso-phosphatidylglycerol, lyso-diphosphatidylglycerol, lyso-phosphatidylserine, lyso-phosphatidylinositol, sphingobase, or a radical of the general formula II
- R 1 are always bonded in the form of their thioesters to the compounds of general formula I.
- R 2 in the general formula II denotes hydrogen, lyso-phosphatidylcholine, lyso-phosphatidylethanolamine, lyso-phosphatidylglycerol, lyso-diphosphatidylglycerol, lyso-phosphatidylserine, lyso-phosphatidylinositol or saturated or unsaturated C2-C2 4 alkylcarbonyl.
- Suitable alkyl radicals are substituted or unsubstituted, saturated or unsaturated C 2 -C 4 -alkylcarbonyl chains such as ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbonyl, n-heptylcarbonyl, n-octylcarbonyl , n-nonylcarbonyl, n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, , n-octadecylcarbonyl, n-nonadec
- C 10 -C 22 -alkylcarbonyl radicals such as n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl , n-octadecylcarbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n-docosanylcarbonyl or n-tetracosanylcarbonyl containing one or more double bond (s) are preferred.
- saturated and / or unsaturated C 1 -C 22 -alkylcarbonyl radicals such as C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, C-12-alkylcarbonyl, C 1 -C 3 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, de-alkylcarbonyl- , C 1 -C 4 -alkylcarbonyl, C 2 -C -alkylcarbonyl or C 2 2 -alkylcarbonyl radicals which contain one or more double bonds.
- C 1 -C 4 -alkylcarbonyl such as C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, C-12-alkylcarbonyl, C 1 -C 3 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, de-alkylcarbonyl-
- C 16 -C 22 -alkylcarbonyl radicals such as C 1 -C 4 -alkylcarbonyl, cis-alkylcarbonyl, C 2 -C 6 -alkylcarbonyl or C 22 -alkylcarbonyl radicals, which contain one or more double bonds.
- These advantageous radicals can contain two, three, four, five or six double bonds.
- the particularly advantageous radicals having 20 or 22 carbon atoms in the Fatty acid chain contain up to six double bonds, advantageously three, four, five or six double bonds, more preferably five or six double bonds. All these radicals are derived from the corresponding fatty acids.
- R 3 in the general formula II is hydrogen, saturated or unsaturated C 2 -C 4 -alkylcarbonyl.
- Suitable alkyl radicals are substituted or unsubstituted, saturated or unsaturated C 2 -C 4 -alkylcarbonyl chains such as ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbonyl, n-heptylcarbonyl, n-octylcarbonyl , n-nonylcarbonyl, n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, , n-octadecylcarbonyl, n-nonadec
- C 10 -C 22 -alkylcarbonyl radicals such as n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, n Octadecylcarbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n -docosanylcarbonyl or n-tetracosanylcarbonyl containing one or more double bonds are preferred.
- saturated and / or unsaturated C 1 -C 22 -alkylcarbonyl radicals such as C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, C-12-alkylcarbonyl, C 1 -C 3 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, de-alkylcarbonyl-, C 1 -C 4 -alkylcarbonyl, C 2 -C -alkylcarbonyl or C 2 2 -alkylcarbonyl radicals which contain one or more double bonds.
- C 1 -C 4 -alkylcarbonyl such as C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, C-12-alkylcarbonyl, C 1 -C 3 -alkylcarbonyl, C 1 -C 4 -alkylcarbonyl, de-alkylcarbonyl-,
- saturated or unsaturated C 16 -C 22 -alkylcarbonyl radicals such as C 16 -alkylcarbonyl, cis-alkylcarbonyl, C 2 -alkylcarbonyl or C 22 -alkylcarbonyl radicals, which contain one or more double bonds.
- These advantageous radicals may contain two, three, four, five or six double bonds.
- Fatty acid chain contain up to six double bonds, advantageously three, four, five or six double bonds, particularly preferably five or six double bonds bonds. All these radicals are derived from the corresponding fatty acids.
- R 1 , R 2 and R 3 may be substituted by hydroxyl and / or epoxy groups and / or may contain triple bonds.
- the polyunsaturated fatty acids prepared in the process according to the invention contain at least two, advantageously three, four, five or six double bonds. Particularly advantageously, the fatty acids contain four, five or six double bonds.
- Fatty acids produced in the process advantageously have 18, 20 or 22 carbon atoms in the fatty acid chain, preferably the fatty acids contain 20 or 22 carbon atoms in the fatty acid chain.
- saturated fatty acids are little or not reacted with the nucleic acids used in the process.
- the saturated fatty acids having less than 5% of the activity advantageously less than 3%, particularly advantageously less than 2%, most preferably less than 1; 0.5; 0.25 or 0.125% are implemented.
- These produced fatty acids can be produced as the only product in the process or present in a fatty acid mixture.
- the substituents R 2 or R 3 in the general formulas I and Il are independently saturated or unsaturated C22-CI8 alkylcarbonyl, particularly advantageously, they are independently unsaturated Ci ⁇ -, C20 or C22 alkylcarbonyl with at least two double bonds.
- the polyunsaturated fatty acids produced in the process are advantageously bound in membrane lipids and / or triacylglycerides, but may also be present as free fatty acids or bound in the form of other fatty acid esters in the organisms. They may be present as "pure products" or advantageously in the form of mixtures of different fatty acids or mixtures of different glycerides.
- the different fatty acids bound in the triacylglycerides can be selected from short-chain fatty acids having 4 to 6 C atoms, medium-chain fatty acids having 8 to 12 C atoms or long-chain Derive fatty acids having 14 to 24 carbon atoms, preferred are the long-chain fatty acids, particularly preferred are the long-chain fatty acids LCPUFAs of Ci8, C20 and / or C22 fatty acids.
- the fatty acid esters with C18, C20 and / or C22 polyunsaturated fatty acid molecules can be prepared from the organisms used for the preparation of the fatty acid esters in the form of an oil or lipid, for example in the form of compounds such as sphingolipids, phosphoglycerides, lipids, Glycolipids such as glycosphingolipids, phospholipids such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol or diphosphatidylglycerol, monoacylglycerides, diacylglycerides, triacylglycerides or other fatty acid esters such as the acetyl-coenzymeA esters containing the polyunsaturated fatty acids containing at least two, three, four, five or six, preferably five or six double bonds, they are advantageously isolated in the form of their di
- the polyunsaturated fatty acids are also known as free fatty acids or bound in other compounds in the organisms, advantageously the plants, contain.
- the various aforementioned compounds (fatty acid esters and free fatty acids) in the organisms in an approximate distribution of 80 to 90 wt .-% triglycerides, 2 to 5 wt .-% diglycerides, 5 to 10 wt .-% monoglycerides, 1 up to 5% by weight of free fatty acids, from 2 to 8% by weight of phospholipids, the sum of the various compounds being supplemented to 100% by weight.
- the LCPUFAs produced are present in a content of at least 3% by weight, advantageously of at least 5% by weight, preferably of at least 8% by weight, more preferably of at least 10% by weight, very particularly preferably at least 15 wt .-% based on the total fatty acids in the transgenic organisms advantageously produced in a transgenic plant.
- Ci ⁇ and / or C2o fatty acids present in the host organisms are at least 10%, advantageously at least 20%, particularly advantageously at least 30%, very particularly advantageously at least 40% in the corresponding products such as DPA or DHA, to name just two.
- the fatty acids are prepared in bound form.
- these unsaturated fatty acids can be brought to the sn1, sn2 and / or sn3 position of the advantageously prepared triglycerides.
- the starting compounds linoleic acid (C18: 2) or linolenic acid (C18: 3) undergo several reaction steps in the process according to the invention, the end products of the process, such as, for example, arachidonic acid (ARA), eicosapentaenoic acid (EPA), .omega.-6-docosapentaenoic acid, are precipitated or DHA not as absolute pure products, there are always also small traces of precursors in the final product included.
- ARA arachidonic acid
- EPA eicosapentaenoic acid
- DHA .omega.-6-docosapentaenoic acid
- both linoleic acid and linolenic acid are present in the starting organism or in the starting plant, for example, the end products such as ARA, EPA or DHA are present as mixtures.
- the precursors should advantageously not more than 20 wt .-%, preferably not more than 15 wt .-%, more preferably not more than 10 wt .-%, most preferably not more than 5 wt .-% based on the amount of the respective Final product amount.
- ARA, EPA or only DHA are advantageously bound in the process according to the invention or as free acids produced.
- the compounds ARA, EPA and DHA are prepared simultaneously, they are advantageously used in a ratio of at least 1: 1: 2 (EPA: ARA: DHA), preferably of at least 1: 1: 3, preferably of 1: 1: 4 preferably prepared from 1: 1: 5.
- Fatty acid esters or fatty acid mixtures which have been prepared by the process according to the invention advantageously contain 6 to 15% palmitic acid, 1 to 6% stearic acid; 7 - 85% oleic acid; 0.5 to 8% of vaccenic acid, 0.1 to 1% of arachidic acid, 7 to 25% of saturated fatty acids, 8 to 85% of monounsaturated fatty acids and 60 to 85% of polyunsaturated fatty acids in each case based on 100% and on the total fatty acid content of organisms.
- fatty acid esters or fatty acid mixtures are preferably at least 0.1; 0.2; 0.3; 0.4; 0.5; 0.6; 0.7; 0.8; 0.9 or 1% based on the total fatty acid content of arachidonic acid. Furthermore, the fatty acid esters or fatty acid mixtures containing after the invention
- fatty acids selected from the group of fatty acids erucic acid (13-docosaoic acid), sterculic acid (9,10-methylene octadec-9-enoic acid), malvalic acid (8,9-methylene heptadec-8-enoic acid), chaulmoogrinic acid (cyclopentene dodecanoic acid), furan fatty acid (9,12-epoxy-octadeca-9,1-dienanoic acid), vernonic acid (9,10-epoxyoctadec-12-enoic acid), taric acid (6-octadecynoic acid), 6-nonadecynoic acid, santalbinic acid ( t1 1-octadecen-9-ynoic acid), 6,9-octadecenynoic acid, pyrulic acid (t10-heptadecene-8-ynonic acid), crepenynic acid (9
- fatty acids are generally advantageously present only in traces in the fatty acid esters or fatty acid mixtures prepared by the process according to the invention, that is to say they come to less than 30%, preferably less than 25%, 24%, 23%, 22% or 21%, more preferably less than 20%, 15%, 10%, 9%, based on the total fatty acids, 8%, 7%, 6% or 5%, most preferably less than 4%, 3%, 2% or 1%.
- nucleic acid sequences according to the invention or the nucleic acid sequences used in the method according to the invention can increase the yield of polyunsaturated fatty acids by at least 50%, advantageously by at least 80%, particularly advantageously by at least 100%, very particularly advantageously by at least 150% compared to the non-transgenic starting organism for example, a yeast, an alga, a fungus or a plant such as Arabidopsis or flax can be achieved in comparison in the GC analysis.
- fatty acids or fatty acid compositions can be prepared by the methods described above.
- the fatty acids or fatty acid compositions from the organism such as the microorganisms or plants or the culture medium in which or on which the organisms were grown, or from the organism and the culture medium in a known manner, for example via extraction, distillation, crystallization, chromatography or Isolated combinations of these methods.
- These chemically pure fatty acids or fatty acid compositions are advantageous for applications in the food industry, the cosmetics industry and especially the pharmaceutical industry.
- genes of the fatty acid or lipid metabolism can advantageously be used in combination with the inventive polynucleotide (in the context of this application the plural is to include the singular and vice versa) in the process for producing polyunsaturated fatty acids.
- Genes are preferably selected from the group of ⁇ -4-desaturases, ⁇ -5-desaturases, ⁇ -6-desaturases, ⁇ -8-desaturases, ⁇ -9-desaturases, ⁇ -12-desaturases, ⁇ -15-desaturases, ⁇ -12 and ⁇ -15-desaturases, ⁇ -3-desaturases, ⁇ -6-elongases, ⁇ -9-elongases or ⁇ -5-elongases used in combination with the polynucleotides according to the invention, wherein single genes or several genes in combination can be used. For particularly preferred gene combinations, reference is made here to Tables 5 and 6 shown in the Examples and the examples.
- the desaturases used in the process of the invention convert their respective substrates in the form of the CoA fatty acid esters.
- the respective desaturation products are thereby synthesized in higher amounts, since the elongation step usually takes place on the CoA fatty acid esters, while the desaturation step takes place predominantly on the phospholipids or on the triglycerides.
- An exchange reaction that would require further possibly limiting enzyme reaction between the CoA fatty acid esters and the phospholipids or triglycerides is thus not required.
- the enzymatic activity of the polypeptides used in the process according to the invention makes it possible to prepare a wide variety of polyunsaturated fatty acids in the process according to the invention.
- the organisms used for the process according to the invention such as the preferred plants, it is possible to use mixtures of the various polyunsaturated fatty acids or individual polyunsaturated fatty acids, such as EPA or ARA produce free or bound form.
- fatty acids derived from C18: 2 fatty acids such as GLA, DGLA or ARA or those derived from C18: 3 Derive fatty acids, such as SDA, ETA or EPA.
- GLA fatty acid derived from C18: 2 fatty acids
- ARA fatty acids derived from C18: 3 Derive fatty acids, such as SDA, ETA or EPA.
- Derive fatty acids such as SDA, ETA or EPA.
- SDA, ETA, EPA and / or DHA can be produced as products of the process, as described above described as free fatty acids or bound.
- ⁇ -5-desaturase By modifying the activity of the enzymes involved in the synthesis ⁇ -5-desaturase, ⁇ -6-desaturase, ⁇ -4-desaturase, ⁇ -12-desaturase, ⁇ 15-desaturase, ⁇ 3-desaturase, ⁇ -5-elongase and / or ⁇ 6-elongase can be produced selectively in the abovementioned organisms advantageously only in the abovementioned plants only individual products. Due to the activity of ⁇ -6-desaturase and ⁇ -6 elongase, for example, GLA and DGLA or SDA and ETA are formed, depending on the starting plant and unsaturated fatty acid. Preference is given to DGLA or ETA or mixtures thereof.
- ARA, EPA and / or DHA are additionally produced.
- ARA, EPA or DHA or their mixtures are synthesized, depending on the fatty acids present in the organism or in the plant, which serves as the starting substance for the synthesis. Since these are biosynthetic chains, the respective end products are not present as pure substances in the organisms. There are always small amounts of precursor compounds in the final product.
- these small amounts are less than 20 wt .-%, advantageously less than 15 wt .-%, more preferably less than 10 wt .-%, most preferably less than 5, 4, 3, 2 or 1 wt .-% based to the end product DGLA, ETA or mixtures thereof or ARA, EPA, DHA or mixtures thereof advantageously EPA or DHA or mixtures thereof.
- the fatty acids can also be fed from the outside. For cost reasons, production in the organism is preferred.
- Preferred substrates are linoleic acid (C18: 2 ⁇ 9 12 ), ⁇ -linolenic acid (C18: 3 ⁇ 6 ' 9 ' 12 ), eicosadienoic acid (C20: 2 ⁇ 11 14 ), dihomo- ⁇ -linolenic acid (C20: 3 ⁇ 8 11 14 ), arachidonic acid (C20: 4 ⁇ 5 8 11 14 ), docosatetraenoic acid (C22: 4 ⁇ 7 10. 13 16 ) and docosapentaenoic acid (C22: 5 ⁇ 4 7 10 13 15 ).
- the genus and species Olea europaea or the family Fabaceae such as the genus Glycine e.g. the genus and species Glycine max, which have a high oleic acid content. Since these organisms have only a low content of linoleic acid (Mikoklajczak et al., Journal of the American Oil Chemical Society, 38, 1961, 678-681) is the use of said ⁇ -12-desaturases and / or ⁇ 15-desaturases according to the invention to Preparation of the starting product linoleic advantageous.
- nucleic acid sequences or their derivatives or homologs which code for polypeptides which still possess the enzymatic activity of the proteins coded by nucleic acid sequences are advantageously used in the process according to the invention.
- These sequences are cloned individually or in combination with the polynucleotides according to the invention in expression constructs and used for introduction and for expression in organisms. By their construction, these expression constructs enable a favorable optimal synthesis of the polyunsaturated fatty acids produced in the process according to the invention.
- the method further comprises the step of obtaining a cell or a whole organism containing the nucleic acid sequences used in the method, wherein the cell and / or the organism with a polynucleotide according to the invention, a gene construct or a vector as described below, alone or in combination with other nucleic acid sequences encoding proteins of the fatty acid or lipid metabolism.
- this method further comprises the step of recovering the oils, lipids or free fatty acids from the organism or from the culture.
- the culture may be, for example, a fermentation culture, for example, in the case of culturing microorganisms such as Mortierella, Thalassiosira, Mantoniella, Ostreococcus, Saccharomyces or Thraustochytrium, or a greenhouse or field crop of a plant.
- the cell or organism thus produced is advantageously a cell of an oil-producing one
- Organism such as an oil crop such as peanut, canola, canola, flax, hemp, peanut, soy, safflower, hemp, sunflower or borage.
- Cultivation is, for example, culturing in the case of plant cells, tissues or organs on or in a nutrient medium or the whole plant on or in a substrate, for example in hydroponics, potting soil or on arable land.
- Suitable organisms or host cells for the process according to the invention are those which are able to synthesize fatty acids, especially unsaturated fatty acids, or are suitable for the expression of recombinant genes.
- plants such as Arabidopsis, Asteraceae such as calendula or crops such as soybean, peanut, castor, sunflower, corn, cotton, flax, rapeseed, coconut, oil palm, dyer safflower (Carthamus tinctorius) or cocoa bean, microorganisms such as fungi, for example the genus Mortierella, Thraustochytri - Saprolegnia, Phytophthora or Pythium, bacteria such as the genus Escherichia or Shewanella, yeasts such as the genus Saccharomyces, cyanobacteria, ciliates, algae such as Mantoniella or Ostreococcus or protozoans such as dinoflagels laten like Thalassiosira or Cry
- transgenic animals are, in addition to the abovementioned transgenic organisms, suitable as host organisms, non-human animals, for example Cae- norhabditis elegans. Other suitable host cells and organisms have previously been described in detail.
- Transgenic plants containing the polyunsaturated fatty acids synthesized in the process according to the invention can advantageously be marketed directly without the synthesized oils, lipids or fatty acids having to be isolated.
- Plants in the process according to the invention include whole plants as well as all plant parts, plant organs or plant parts such as leaves, stems, seeds, roots, tubers, anthers, fibers, root hairs, stems, embryos, cilia, kotelydones, petioles, crop material, plant tissue, reproductive Tissues, cell cultures derived from the transgenic plant and / or used to produce the transgenic plant.
- the seed includes all seed parts such as the seed shells, epidermis and sperm cells, endosperm or embryonic tissue.
- the compounds prepared in the process according to the invention can also be isolated from the organisms advantageously plants in the form of their oils, fat, lipids and / or free fatty acids.
- Polyunsaturated fatty acids produced by this process can be harvested by harvesting the organisms either from the culture in which they grow or from the field. This can be done by pressing or extraction of the plant parts, preferably the plant seeds.
- the oils, fats, lipids and / or free fatty acids can be obtained by so-called cold pressing or cold pressing without supplying heat by pressing.
- the plant parts, especially the seeds, to be easier to digest they are first crushed, steamed or roasted. The pretreated seeds can then be pressed or with Solvents such as warm hexane are extracted.
- the solvent is removed again.
- these are harvested after harvesting, for example, directly without further working steps, or else extracted after digestion by various methods known to the person skilled in the art. In this way, more than 96% of the compounds prepared in the process can be isolated.
- the products thus obtained are further processed, that is refined.
- the mucilages and turbid matter are removed.
- the so-called degumming can be carried out enzymatically or, for example, chemically / physically by adding acid such as phosphoric acid. Subsequently, the free fatty acids pass through
- the PUFAs or LCPUFAs produced by this process are Ci8, C20 or C22 fatty acid molecules, advantageously C20 or C22 fatty acid molecules having at least two double bonds in the fatty acid molecule, preferably three, four, five or six double bonds.
- These C-m, C20 or C22 fatty acid molecules can be isolated from the organism in the form of an oil, lipid or free fatty acid. Suitable organisms are, for example, those mentioned above. Preferred organisms are transgenic plants.
- oils, lipids or fatty acids or fractions thereof which have been prepared by the method described above, more preferably oil, lipid or fatty acid composition comprising PUFAs derived from transgenic plants.
- oils, lipids or fatty acids advantageously contain 6 to 15% palmitic acid, 1 to 6% stearic acid as described above; 7 - 85% oleic acid; 0.5 to 8% of vacic acid, 0.1 to 1% of arachidic acid, 7 to 25% of saturated fatty acids, 8 to 85% of monounsaturated fatty acids and 60 to 85% of polyunsaturated fatty acids in each case based on 100% and on the total fatty acid content of the organisms.
- polyunsaturated fatty acid in the fatty acid ester or fatty acid mixtures are preferably at least 0.1; 0.2; 0.3; 0.4; 0.5; 0.6; 0.7; 0.8; 0.9 or 1% based on the total fatty acid content of arachidonic acid.
- the fatty acid esters or fatty acid mixtures prepared by the process according to the invention advantageously contain fatty acids selected from the group of the fatty acids erucic acid (13-docosaoic acid), sterculinic acid (9,10-methylene octadec-9-enoic acid), malvalic acid (8 , 9-methylene heptadec-8-enoic acid), chaulmoogric acid (cyclopentene-dodecanoic acid), furan fatty acid (9,12-epoxy-octadeca-9,1 1 -dienoic acid), vernonoic acid (9,10-epoxy-octadec-12- enoic acid), taric acid (6-octadecynoic acid), 6-nonadecynoic acid, santalbinic acid (t1-octadecen-9-ynoic acid), 6,9-octadecenynoic acid, pyrul
- fatty acids are generally advantageously present only in traces in the fatty acid ester or fatty acid mixtures prepared by the process according to the invention, that is to say they are less than 30%, preferably less than 25%, 24%, based on the total fatty acids. 23%, 22% or 21%, more preferably less than 20%, 15%, 10%, 9%, 8%, 7%, 6% or 5%, most preferably less than 4%, 3%, 2% or 1% before.
- the oils, lipids or fatty acids according to the invention preferably contain at least 0.5%, 1%, 2%, 3%, 4% or 5%, advantageously at least 6%, 7%, 8%, 9% or 10%, particularly advantageously at least 1 1%, 12%, 13%, 14% or 15% ARA or at least 0.5%, 1%, 2%, 3%, 4% or 5%, advantageously at least 6%, or 7%, most preferably at least 8%, 9% or 10% EPA and / or DHA relative to the total fatty acid content of the production organism, advantageously a plant, particularly advantageously an oil crop such as soybean, oilseed rape, coconut, oil palm, safflower, flax, hemp, castor, calendula, peanut, Cocoa bean, sunflower or the above-mentioned further monocotyledonous or dicotyledonous oil crop plants.
- an oil crop such as soybean, oilseed rape, coconut, oil palm, safflower, flax, hemp, castor,
- Another embodiment of the invention is the use of the oil, lipid, fatty acids and / or fatty acid composition in feed, food, cosmetics or pharmaceuticals.
- the oils, lipids, fatty acids or fatty acid mixtures according to the invention may be mixed with other oils, lipids, fatty acids or fatty acid mixtures of animal origin, such as those described in the art, for example. Fish oils are used. These oils, lipids, fatty acids or fatty acid mixtures, which consist of vegetable and animal components, can be used for the production of feed, food, cosmetics or pharmaceuticals.
- oil is understood as meaning a fatty acid mixture which contains unsaturated, saturated, preferably esterified fatty acid (s). It is preferred that the oil, lipid or fat contain a high proportion of polyunsaturated free or advantageously esterified fatty acid (s), especially linoleic acid, ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, arachidonic acid, ⁇ -linolenic acid, stearidonic acid, eicosatetraenoic acid, Eicosapentaenoic acid, docosapentaenoic acid or docosahexaenoic acid.
- s polyunsaturated free or advantageously esterified fatty acid
- the proportion of unsaturated esterified fatty acids is about 30%, more preferred is a proportion of 50%, even more preferred is a proportion of 60%, 70%, 80% or more.
- the proportion of fatty acid after conversion of the fatty acids into the methyl esters can be determined by transesterification by gas chromatography.
- the oil, lipid or fat may contain various other saturated or unsaturated fatty acids, eg calendulic acid, Palmitin, palmitoleic, stearic, oleic acid, etc., included. In particular, depending on the starting organism, the proportion of the various fatty acids in the oil or fat may vary.
- the polyunsaturated fatty acids having advantageously at least two double bonds prepared in the process are, as described above, for example sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids, monoacylglycerol, diacylglycerol, triacylglycerol or other fatty acid esters.
- the polyunsaturated fatty acids containing, for example, an alkali treatment such as aqueous KOH or NaOH or acid hydrolysis advantageously in the presence of an alcohol such as methanol or ethanol or via an enzymatic cleavage liberate and isolate via, for example, phase separation and subsequent acidification via, for example, H 2 SO 4 .
- an alkali treatment such as aqueous KOH or NaOH or acid hydrolysis
- an alcohol such as methanol or ethanol or via an enzymatic cleavage
- the release of the fatty acids can also be carried out directly without the workup described above.
- the nucleic acids used in the method can advantageously be either a plant cell or plant, either on a separate plasmid or advantageously integrated into the genome of the host cell.
- integration may be at random or by such recombination as to replace the native gene with the incorporated copy, thereby modulating the production of the desired compound by the cell, or by using a gene in "trans" in that the gene is functionally linked to a functional expression unit which contains at least one sequence ensuring the expression of a gene and at least one sequence ensuring the polyadenylation of a functionally transcribed gene
- the nucleic acids are transferred via multiexpression cassettes or constructs for multiparallel expression in the Organisms advantageous for multiparallel seed-specific expression of genes brought into the plants.
- Moose and algae are the only known plant systems that produce significant amounts of polyunsaturated fatty acids, such as arachidonic acid (ARA) and / or eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).
- ARA arachidonic acid
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- Moose contain PUFAs in membrane lipids, while algae, algae-related organisms and some fungi also accumulate significant levels of PUFAs in the triacylglycerol fraction.
- nucleic acid molecules isolated from strains which also accumulate PUFAs in the triacylglycerol fraction are particularly advantageous for the process of the invention and thus for modification of the lipid and PUFA production system in a host, in particular plants such as oilseed crops, for example oilseed rape. Canola, flax, hemp, soy, sunflower, borage. They are therefore advantageous for use in the process according to the invention.
- acyl-CoA-dehydrogenase acyl-ACP [acyl carrier protein] desaturase
- acyl-ACP-thioesterase acyl-ACP-thioesterase
- Acid Acyltransferase s
- Fatty Acid acyl-CoA-dehydrogenase (s)
- acyl-ACP acyl carrier protein] desaturase
- acyl-ACP-thioesterase acyl-ACP-thioesterase
- Acid Acyltransferase s
- Acyl-CoA Lysophospholipid Acyltransferase (s)
- Synthase (s), fatty acid hydroxylase (s), acetyl coenzyme A carboxylase (s), acyl coenzyme A oxidase (s), fatty acid desaturase (s), fatty acid acetylenase (s), lipoxygenase (s) , Triacylglycerol lipase (s), allene oxide synthase (s), hydroperoxide lyase (s) or fatty acid elongase (s) are preferably Cie, Ci ⁇ - or C20 fatty acids.
- the fatty acids reacted as substrates in the process are preferably reacted in the form of their acyl-CoA esters and / or their phospholipid esters.
- the polyunsaturated cis-fatty acids must first be desaturated by the enzymatic activity of a desaturase and then be extended by at least two carbon atoms via an elongase. After one round of elongation, this enzyme activity leads to C2O fatty acids, and after two elongation round to C22 fatty acids.
- the desaturases and elongases used in the activity of the processes according to the invention preferably lead to C 16-, C 20- and / or C 22 -fatty acids advantageously having at least two double bonds in the fatty acid molecule, preferably having three, four, five or six double bonds, more preferably C 20- and / or C22 fatty acids having at least two double bonds in the fatty acid molecule, preferably having three, four, five or six double bonds, very particularly preferably having five or six double bonds in the molecule.
- further desaturation and elongation steps such as desaturation at ⁇ -5 and ⁇ -4 positions may occur.
- Particularly preferred as products of the process according to the invention are dihomo- ⁇ -linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and / or docosahexaenoic acid.
- the C2o fatty acids having at least two double bonds in the fatty acid can be desaturated by the enzymatic activity according to the invention in the form of the free fatty acid or in the form of the esters, such as phospholipids, glycolipids, sphingolipids, phosphoglycides, monoacylglycerol, diacylglycerol or triacylglycerol.
- the preferred biosynthesis site of fatty acids, oils, lipids or fats in the advantageously used plants is, for example, generally the seeds or cell layers of the seed, so that a seed-specific expression of the nucleic acids used in the method is useful.
- biosynthesis of fatty acids, oils or lipids need not be limited to the seed tissue, but may also be tissue-specific in all other parts of the plant - for example in epidermal cells or in the tubers.
- organisms such as microorganisms such as yeasts such as Saccharomyces or Schizosaccharomyces, fungi such as Mortierella, Aspergillus, Phytophtora, Entomophthora, Mucor or Thraustochytrium algae such as Isochrysis, Mantoniella, Ostreococcus, Phaeodactylum or Crypthecodiniu be used in the process according to the invention, these organisms are advantageously attracted to fermentation.
- yeasts such as Saccharomyces or Schizosaccharomyces
- fungi such as Mortierella, Aspergillus, Phytophtora, Entomophthora, Mucor or Thraustochytrium algae such as Isochrysis, Mantoniella, Ostreococcus, Phaeodactylum or Crypthecodiniu be used in the process according to the invention, these organisms are advantageously attracted to fermentation.
- the polyunsaturated fatty acids produced in the process can be at least 5%, preferably at least 10%, particularly preferably at least 20%, very particularly preferably at least 50%, compared to the wild-type Organisms that do not contain the nucleic acids recombinantly increased.
- the polyunsaturated fatty acids produced in the organisms used in the process can in principle be increased in two ways.
- the pool of free polyunsaturated fatty acids and / or the proportion of esterified polyunsaturated fatty acids produced by the process can be increased.
- the process according to the invention increases the pool of esterified polyunsaturated fatty acids in the transgenic organisms.
- microorganisms are used as organisms in the process according to the invention, they are grown or grown, depending on the host organism, in a manner known to the person skilled in the art.
- Microorganisms are usually in a liquid medium containing a carbon source usually in the form of sugars, a nitrogen source usually in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese, magnesium salts and optionally vitamins, at temperatures between 0 0 C and 100 0 C, preferably between 1O 0 C to 6O 0 C attracted under oxygen fumigation.
- the pH of the nutrient fluid can be kept at a fixed value, that is regulated during the cultivation or not.
- the cultivation can be batchwise, semi-batch wise or continuous. Nutrients can be presented at the beginning of the fermentation or fed in semi-continuously or continuously.
- the polyunsaturated fatty acids prepared can be isolated from the organisms by methods known to those skilled in the art, as described above. For example, extraction, distillation, crystallization, optionally salt precipitation and / or chromatography. The organisms can be opened up for this purpose yet advantageous.
- the inventive method, when it is in the host organisms are microorganisms, advantageously at a temperature between 0 ° C to 95 °, preferably between 1 O 0 C to 85 0 C, more preferably between 15 0 C to 75 0 C, most particularly preferably carried out between 15 0 C to 45 0 C.
- the pH is advantageously maintained between pH 4 and 12, preferably between pH 6 and 9, more preferably between pH 7 and 8.
- the process according to the invention can be operated batchwise, semi-batchwise or continuously.
- a summary of known cultivation methods is in the textbook by Chmiel (Bioreatechnik 1. Introduction to bioprocess engineering (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (bioreactors and peripheral facilities (Vieweg Verlag, Braunschweig / Wiesbaden, 1994)) Find.
- the culture medium to be used must suitably satisfy the requirements of the respective strains. Descriptions of culture media of various microorganisms are contained in the Manual of Methods for General Bacteriology of the American Society for Bacteriology (Washington D.C, USA, 1981).
- these media which can be used according to the invention usually comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.
- Preferred carbon sources are sugars, such as mono-, di- or polysaccharides.
- sugars such as mono-, di- or polysaccharides.
- very good carbon sources are glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose.
- Sugar can also be added to the media via complex compounds, such as molasses, or other by-products of sugar refining. It may also be advantageous to add mixtures of different carbon sources.
- oils and fats such as soybean oil, sunflower oil, peanut oil and / or coconut oil, fatty acids such as palmitic acid, stearic acid and / or linoleic acid, alcohols and / or polyalcohols such as As glycerol, methanol and / or ethanol and / or organic acids such as acetic acid and / or lactic acid.
- Nitrogen sources are usually organic or inorganic nitrogen compounds or materials containing these compounds.
- Exemplary nitrogen sources include ammonia in liquid or gas form or ammonium salts such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources such as corn steep liquor, soybean meal, soy protein, yeast extract, meat extract and others.
- the nitrogen sources can be used singly or as a mixture.
- Inorganic salt compounds which may be included in the media include the chloride, phosphorus or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
- sulfur-containing fine chemicals in particular methionine
- inorganic sulfur-containing compounds such as sulfates, sulfites, dithionites, tetrathionates, thiosulfates, sulfides but also organic sulfur compounds, such as mercaptans and thiols can be used.
- Phosphoric acid potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the phosphorus source.
- Chelating agents can be added to the medium to keep the metal ions in solution.
- Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
- the fermentation media used according to the invention for the cultivation of microorganisms usually also contain other growth factors, such as vitamins or growth promoters, to which, for example, biotin, riboflavin, Thiamine, folic acid, nicotinic acid, panthothenate and pyridoxine belong.
- Growth factors and salts are often derived from complex media components, such as yeast extract, molasses, corn steep liquor, and the like.
- suitable precursors can be added to the culture medium.
- the exact composition of the media compounds depends strongly on the particular experiment and is decided individually for each specific case. Information about the media optimization is available from the textbook "Applied Microbiol Physiology, A Practical Approach” (Ed PM Rhodes, PF Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3).
- Growth media may also be obtained from commercial suppliers such as Standard 1 (Merck) or BHI (Brain heart infusion, DIFCO) and the like.
- All media components are sterilized either by heat (20 min at 1, 5 bar and 121 0 C) or by sterile filtration.
- the components can either be sterilized together or, if necessary, sterilized separately. All media components may be present at the beginning of the culture or optionally added continuously or batchwise.
- the temperature of the culture is usually between 15 0 C and 45 0 C, preferably at 25 0 C to 40 0 C and can be kept constant or changed during the experiment.
- the pH of the medium should be in the range of 5 to 8.5, preferably around 7.0.
- the pH for cultivation can be controlled during cultivation by addition of basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acidic compounds such as phosphoric acid or sulfuric acid. To control the foam development antifoams such. As fatty acid polyglycol, are used.
- the medium can be selected selectively acting substances such. As antibiotics, are added.
- oxygen or oxygen-containing gas mixtures, such as ambient air are introduced into the culture.
- the temperature of the culture is normally from 2O 0 C to 45 0 C and preferably at 25 0 C to 40 0 C. The culture is continued until a maximum of the desired Product has formed. This goal is usually reached within 10 hours to 160 hours.
- the fermentation broths thus obtained in particular containing polyunsaturated fatty acids, usually have a dry matter content of 7.5 to 25% by weight.
- the fermentation broth can then be further processed.
- the biomass can be wholly or partly by separation methods, such. As centrifugation, filtration, decantation or a combination of these methods are removed from the fermentation broth or completely left in it.
- the biomass is worked up after separation.
- the fermentation broth can also without cell separation with known methods such. B. with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, or by nanofiltration, thickened or concentrated. This concentrated fermentation broth may eventually be worked up to recover the fatty acids contained therein.
- polynucleotides or polypeptides of the present invention which are involved in the metabolism of lipids and fatty acids, PUFA cofactors and enzymes or in the transport of lipophilic compounds via membranes, are advantageously used in plants according to the invention for modulating the production of PUFAs in transgenic organisms
- Solanacaen Plants such as potato, tobacco, aubergine and tomato, Vicia species, pea, cassava, alfalfa, bush plants (coffee, cocoa, tea), Salix species, trees (oil palm, coconut) and perennial grasses and forage crops, either directly ( For example, when overexpression or optimization of a fatty acid biosynthesis protein has a direct impact on the yield
- PUFAs polyunsaturated fatty acids
- Brasicaceae Particularly suitable for the production of PUFAs, for example stearidonic acid, eicosapentaenoic acid and docosahexaenoic acid, are Brasicaceae, boraginaceous plants, primulaceae or linaceae.
- Lein Lium usitatis simum is particularly advantageously suitable for the production of PUFAS with the nucleic acid sequences according to the invention, as described, in combination with other desaturases and elongases.
- the lipid synthesis can be divided into two sections: the synthesis of fatty acids and their attachment to sn-glycerol-3-phosphate and the addition or modification of a polar head group.
- Common lipids used in membranes include phospholipids, glycolipids, sphingolipids and phosphoglycerides.
- Fatty acid synthesis begins with the conversion of acetyl-CoA into malonyl-CoA by the acetyl-CoA carboxylase or into acetyl-ACP by the acetyl transacylase.
- Precursors for the PUFA biosynthesis are, for example, oleic acid, linoleic acid and
- Ci8 carbon fatty acids must be extended to C20 and C22 to obtain Eicosa and Docosa chain-type fatty acids.
- desaturases used in the process such as the ⁇ -12, ⁇ -15, ⁇ -12 and ⁇ -15, ⁇ -3, ⁇ -4, ⁇ -5 and ⁇ -6 desaturases and / or Of the ⁇ -5, ⁇ -6 elongases, auric acid, eicosapentaenoic acid, docosapentaenoic acid or docosaphaenoic acid can advantageously be produced eicosapentaenoic acid and / or docosahexaenoic acid and subsequently used for various purposes in food, feed, cosmetic or pharmaceutical applications.
- C20 and / or C22 fatty acids having at least two, preferably at least three, four, five or six double bonds in the fatty acid molecule, preferably C20 or C22 fatty acids with advantageously four, five or six double bonds in the fatty acid molecule can be produced with the abovementioned enzymes.
- the desaturation can take place before or after elongation of the corresponding fatty acid.
- the products of desaturase activities and possible further desaturation and elongation result in preferred PUFAs having a higher desaturation level, including a further elongation of C20 to C22 fatty acids, to fatty acids such as ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, arachidonic acid, stearidonic acid, Eicosatetraenoic acid or eicosapentaenoic acid.
- Substrates of the desaturation used grasses and elongases in the process according to the invention are C16, C18 or C20 fatty acids, for example linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, eicosatetraenoic acid or stearidonic acid.
- Preferred substrates are linoleic acid, ⁇ -linolenic acid and / or ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid or arachidonic acid, eicosatetraenoic acid or eicosapentaenoic acid.
- the synthesized C20 or C22 fatty acids having at least two, three, four, five or six double bonds in the fatty acid are obtained in the novel process in the form of the free fatty acid or in the form of their esters, for example in the form of their glycerides.
- glycolide is understood to mean a glycerol esterified with one, two or three carboxylic acid residues (mono-, di- or triglyceride).
- glycolide is also meant a mixture of different glycerides.
- the glyceride or glyceride mixture may contain other additives, e.g. contain free fatty acids, antioxidants, proteins, carbohydrates, vitamins and / or other substances.
- a "glyceride” in the sense of the method according to the invention is also understood to mean derivatives derived from glycerol.
- these also include glycerophospholipids and glyceroglycolipids.
- the glycerophospholipids such as lecithin (phosphatidylcholine), cardiolipin, phosphatidylglycerol, phosphatidylserine and alkylacylglycerophospholipids may be mentioned here by way of example.
- fatty acids must then be transported to various modification sites and incorporated into the triacylglycerol storage lipid.
- Another important step in lipid synthesis is the transfer of fatty acids to the polar head groups, for example by glycerol-fatty acid acyltransferase (see Frentzen, 1998, Lipid, 100 (4-5): 161-166).
- Beta oxidation, fatty acid modification and cofactors, triacylglycerol storage and assembly including references therein, see the following articles: Kinney, 1997, Genetic Engineering, eds .: JK Setlow, 19: 149-166; Ohlrogge and Browse, 1995, Plant Cell 7: 957-970; Shanklin and Cahoon, 1998, Annu. Rev. Plant Physiol. Plant Mol. Biol. 49: 61-641; Voelker, 1996, Genetic Engineering, eds .: JK Setlow, 18: 1 1 1 -13; Gerhardt, 1992, Prog. Lipid R. 31: 397-417; Gühnemann-Schäfer & Kindl, 1995, Biochim.
- the PUFAs produced in the process comprise a group of molecules that are no longer able to synthesize, and therefore need to take up, higher animals, or that are no longer capable of self-sufficient production, although they are readily synthesized by other organisms, such as bacteria , For example, cats can no longer synthesize arachidonic acid.
- Phospholipids in the context of the invention are to be understood as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol and / or phosphatidylinositol, advantageously phosphatidylcholine.
- production or productivity are known in the art and include the concentration of the fermentation product (compounds of the formula I) , which is formed in a certain period of time and a certain fermentation volume (eg kg of product per hour per liter). It also includes productivity within a plant cell or plant, that is, the content of the desired fatty acids produced in the process based on the content of all fatty acids in that cell or plant.
- the term "efficiency of production” includes the time required to reach a certain amount of production (eg, how long the cell takes to establish a given throughput rate of a fine chemical.)
- yield or product / carbon yield is used in the In the art and includes the efficiency of converting the carbon source into the product (ie, the fine chemical). This is usually expressed, for example, as kg of product per kg of carbon source.
- biosynthesis or biosynthetic pathway are well known in the art and include the synthesis of a compound, preferably an organic compound, by a cell from intermediates, for example in a multi-step and highly regulated process
- degradation or degradation pathway are known in the art and comprise cleavage of a compound, preferably an organic compound, by a cell into degradation products (more generally, smaller or less complex molecules), for example in a multi-step and highly regulated process.
- metabolism is known in the art and encompasses the entirety of the biochemical reactions that take place in an organism.
- the metabolism of a particular compound eg, the metabolism of a fatty acid
- the metabolism of a particular compound then comprises the entirety of the biosynthesis, modification, and degradation pathways of that compound the cell that affects this connection.
- the yield, production and / or efficiency of the production of the polyunsaturated fatty acids in a plant, preferably in an oil crop, or a microorganism can be influenced.
- the number or activity of the polypeptides or polynucleotides according to the invention can be increased, so that larger amounts of the gene products and thus ultimately larger amounts of the compounds of general formula I are produced. Also, a de novo synthesis in an organism lacking the activity and ability to biosynthesize the compounds before introducing the gene (s) of interest is possible.
- a polynucleotide according to the invention By introducing a polynucleotide according to the invention into an organism, alone or in combination with other genes in a cell, not only the biosynthesis flux to the end product can be increased, but also the corresponding triacylglycerol composition can be increased or created de novo. Likewise, the number or activity of other genes necessary for the import of nutrients necessary for the biosynthesis of one or more fatty acids, oils, polar and / or neutral lipids may be increased, such that the concentration of these precursors, cofactors or intermediates within the cells or within the storage compartment, thereby further increasing the ability of the cells to produce PUFAs.
- fatty acids obtained in the process are suitable as starting material for the chemical synthesis of other valuable products. They may be used, for example, in combination with each other or solely for the manufacture of pharmaceuticals, foods, animal feed or cosmetics.
- the invention also relates to a process for preparing an oil, lipid or fatty acid composition comprising the steps of the process of the invention and the further step of formulating the substance as an oil, lipid or fatty acid composition.
- the oil, lipid or fatty acid composition is further formulated into a medicament, to cosmetics, to a food, to a feed, preferably fish feed, or to a dietary supplement.
- the invention generally relates to the use of the polynucleotide, the vector, the host cell, the polypeptide or the transgenic non-human organism of the present invention for the preparation of an oil, lipid or fatty acid composition. This is then preferred to use as medicines, cosmetics, food, feed, preferably fish food, or dietary supplements.
- FIG. 2 Chromatogram of seeds of a rape plant transformed with the construct LJB765 described in the examples.
- untransformed rapeseed only 16: 0, 16: 1, 18: 0, 18: 1, 18: 2n-6, 18: 3n-3, 20: 0, 20: 1, 20: 2n-6 and 22 : 0 are detected.
- the chromatogram confirms the production of new fatty acids in the transgenic rapeseed. These new fatty acids are due to the activity of the introduced genes (see EPA, eicosapentaenoic acid).
- FIG. 3 Chromatogram of seeds of transgenic Arabidopsis plants, transformed with the plasmid LJB765 described in the examples. Similar values for the omega3 fatty acid EPA as in rape could be obtained.
- Figure 4 Gas chromatographic determination of the fatty acids from yeast, with the plasmid pYES (A) or pYES-d12Des (Nh) (B), pYES-d12Des (Mb) (C), pYES-d12Des (Mg) (D) and pYES-d12Des (Pb) (E) were transformed.
- FIG. 5 Gas chromatographic determination of the fatty acids from yeasts treated with the plasmid pYES (A) or pYES-d15Des (Nh) 2 (B), pYES-d15Des (Mg) (C), pYES-d15Des (Hr) (D) , pYES-d15Des (Lg) (E) and pYES-d15Des (Mc) (F).
- the fatty acid 18: 2n-6 was fed in.
- FIG. 6 Gas chromatographic determination of the yeast fatty acids transformed with the plasmid pYES (A) or pYES-d15Des (Hr) (B), pYES-d15Des (Lg) (C) and pYES-d15Des (Mc) (D) were.
- FIG. 7 Gas chromatographic determination of the fatty acids from yeast, which is transformed with the plasmid pYES (A) or pYES-d15Des (Hr) (B), pYES-d15Des (Lg) (C) and pYES-d15Des (Mc) (D) were.
- FIG. 8 Gas chromatographic determination of the fatty acids from Arabidopsis seeds of the fad3 mutant treated with the plasmid pSUN (A) or pSUN-d15Des (Mg) (SEQ ID No. 183; B) and pYES-d15Des (Nh) 2 (SEQ ID No. 184; C).
- Example 1 General Cloning Methods
- the cloning methods such as restriction cleavage, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linkage of DNA fragments, transformation of Escherichia coli cells, culture of bacteria and sequence analysis of recombinant DNA were as in Sambrook et al. (1989) (CoId Spring Harbor Laboratory Press: ISBN 0-87969-309-6).
- the sequencing of recombinant DNA molecules was carried out with a laser fluorescence DNA sequencer from ABI according to the method of Sanger (Sanger et al. (1977) Proc. Natl. Acad., See, USA74, 5463-5467). Fragments resulting from a polymerase chain reaction were sequenced and checked to avoid polymerase errors in constructs to be expressed.
- the effect of genetic modification in plants, fungi, algae, ciliates or on the production of a desired compound may be determined by cultivating the modified microorganism or modified plant under suitable conditions (such as those described above), and Medium and / or the cellular components on the increased production of the desired product (ie of lipids or a fatty acid) is examined.
- suitable conditions such as those described above
- These analytical techniques are well known to those skilled in the art and include spectroscopy, thin layer chromatography, staining methods of various types, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, Vol. A2, pp. 89-90 and p.
- the analytical methods include measurements of nutrient levels in the medium (eg, sugars, hydrocarbons, nitrogen sources, phosphate and other ions), measurements of biomass composition and growth, analysis of production of common biosynthetic pathway metabolites, and measurements of gases generated during fermentation. Standard methods for these measurements are in Applied Microbial Physiology; A Practical Approach, PM Rhodes and PF Stanbury, Eds., IRL Press, pp. 103-129; 131-163 and 165-192 (ISBN: 0199635773) and references cited therein.
- FAME fatty acid methyl ester
- GC-MS gas-liquid chromatography-mass spectrometry
- TAG triacylglycerol
- TLC thin-layer chromatography
- the material to be analyzed may be broken up by sonication, milling in the glass mill, liquid nitrogen and milling or other applicable methods.
- the material must be centrifuged after it has been broken open.
- the sediment is distilled in aqua. resuspended, heated for 10 minutes at 100 0 C, cooled on ice and centrifuged again followed by extraction in 0.5 M sulfuric acid in methanol with 2% dimethoxypropane for 1 hr. at 9O 0 C, which leads to hydrolyzed oil and lipid compounds, which give transmethylated lipids.
- fatty acid methyl esters are extracted into petroleum ether and finally subjected to GC analysis using a capillary column (Chrompack, WCOT Fused silica, CP-Wax-52 CB, 25 microm, 0.32 mm) at a temperature gradient between 17O 0 C and 24O 0 C for 20 min and 5 min at 24O 0 C subjected.
- Chropack Chrompack, WCOT Fused silica, CP-Wax-52 CB, 25 microm, 0.32 mm
- the identity of the resulting fatty acid methyl esters must be defined using standards available from commercial sources (e.g., Sigma).
- T (YF) (LM) HH (HTSV) (G -) ( HY -) (HDEG) "(SEQ ID NO: 1 17), in particular with reference to motif 9" T (YF) (LM) HH (HTS) (HDE) "(SEQ ID NO: 1 18) or alternatively with reference to motif 10 "T (YF) (LM) HH (HTSV) G (HY) (HDEG)” (SEQ ID 1 19), d15 desaturases were identified.
- Omega 3 desaturases were preferably identified on the basis of motif 1 1 "TXXHHNX” (SEQ ID NO: 120), in particular with reference to the motif 12 "T (YF) (LM) HHN (HDEG)” (SEQ ID NO: 121).
- a first step complete genomic sequences corresponding to database entries were identified.
- the coding sequence was extracted on the basis of bioinformatic methods. In order to obtain the corresponding coding sequence from the organisms, it is possible to amplify from cDNA preparations with the primer sequences defined in Table 1 in a PCR reaction. In this case, fragments can be obtained, as described in Table 2.
- Table 1 Primer sequences for the cloning of the identified desaturases.
- Table 2 Coding polynucleotide or amino acid sequences of the identified desaturases.
- Table 3 Genomic sequences of the identified desaturases.
- the open reading frame of the DNA (Table 2) is cloned downstream of the galactose-inducible GAL1 promoter of pYES2.1 / V5-His-TOPO (Invitrogen), the plasmids pYES-D12Des (Nh) , pYES-D15Des (Nh), pYES-D15Des (Tr), pYES-D12Des (Mb), pYES-D15Des (Mg), pYES-D12Des (Mg), pYES-D15Des (Ng), pYES-D12Des (Pb), pYES-D15Des (Nv), pYES-D15Des (Lb), pYES-D15Des (Hr), pYES-D15Des (Lg) 1, pYES-D15Des (Lg) 2, pYES-D15Des (
- plasmids can then be transformed according to the manufacturer's instructions into the yeast strain INVSC-1 (Invitrogen) and selected on plates with DOB-U agar based on uracil auxotrophy. Positive colonies are identified by PCR. This is done in each case with 1 ul thawed cells, 200 uM dNTPs, 2.5 U Taq polymerase and 100 pmol of each primer in a total volume of 50 ul.
- the conditions for the PCR are as follows: first denaturation at 95 ° C. for 5 minutes, followed by 30 cycles at 94 ° C. for 30 seconds, 55 ° C. for 1 minute and 72 ° C. for 2 minutes, and a final extension step at 72 0 C for 10 minutes.
- the empty vector pYES2.1 / V5-His-TOPO is transformed in the manner described into competent yeast cells of the strain INVSC-1.
- the yeast cells from the main cultures are (100 ⁇ g, 5 min, 2O 0 C) harvested by centrifugation and washed with 100 mM NaHCO 3, pH 8.0 to remove residual medium and fatty acids.
- fatty acid methyl esters (FAMEs) are produced by acid methanolysis.
- the cell sediments are incubated with 2 ml of 1 N methanolic sulfuric acid and 2% (v / v) dimethoxypropane for 1 h at 8O 0 C.
- Extraction of the FAMES is carried out by extracting twice with petroleum ether (PE).
- the organic phases are each washed once with 2 ml of 100 mM NaHCO 3 , pH 8.0 and 2 ml of distilled water. washed. Subsequently, the PE phases were dried with Na 2 SO 4 , evaporated under argon and taken up in 100 ⁇ l of PE. Samples are supported on a DB-23 capillary column (30 m, 0.25 mm, 0.25 ⁇ m, Agilent) in a Hewlett-Packard 6850 gas chromatograph
- the signals are identified by comparison of the retention times with corresponding fatty acid standards (Sigma).
- the methodology is described, for example, in Napier and Michaelson, 2001, Lipids. 36 (8): 761-766; Sayanova et al., 2001, Journal of Experimental Botany. 52 (360): 1581-1585, Sperling et al., 2001, Arch. Biochem. Biophys. 388 (2): 293-298 and Michaelson et al., 1998, FEBS Letters. 439 (3): 215-218.
- Table 4A lists the conversion of various fatty acid substrates to the expected fatty acid products. In addition to the fatty acid 18: 1 n-9, all substrates were fed in the experiment and are therefore present in excess. Figures 4, 5, 6 and 7 show the chromatograms of the individual experiments.
- yeasts were transformed with the pYES empty vector and the fatty acid profile analyzed ( Figure 4A).
- the additional fatty acid 18: 2n-6 is observed ( Figure 4B, 4C, 4D, 4E ).
- yeasts were transformed with the pYES empty vector, fed the fatty acid 18: 2n-6 and the fatty acid profile analyzed ( Figure 5A).
- yeast expressing the desaturases d15Des (Nh) 2, d15Des (Mg), d15Des (Hr), d15Des (Lg), and d15Des (Mc) the additional fatty acid 18: 3n-3 is observed ( Figure 5B , 5C, 5D, 5E, 5F).
- These tested desaturases therefore have ⁇ 15-desaturase activity.
- yeasts were transformed with the pYES empty vector, fed the fatty acid 20: 2n-6 and the fatty acid profile analyzed ( Figure 6A).
- yeast expressing the desaturases d15Des (Hr), d15Des (Lg), d15Des (Mc) the additional fatty acid 20: 3n-3 is observed ( Figure 6B, 6C, 6D).
- yeasts were transformed with the pYES empty vector, fed the fatty acid 20: 4n-6, and the fatty acid profile analyzed ( Figure 7A).
- yeast expressing the desaturases d15Des (Hr), d15Des (Lg), d15Des (Mc) the additional fatty acid 22: 5n-3 is observed ( Figure 7B, 7C, 7D).
- Table 4B Position of the region of the binary vector pSUN-d15Des (Mg) (16093 bp, DNA, circular), which encodes the desaturase d15Des (Mg) (SEQ ID NO: 15), as well as the position of the corresponding expression-regulating promoter and promoter terminator.
- the underlying basis vector is pSUN.
- the position indicated describes the start and end point of the corresponding element in base pairs (bp) with reference to SEQ ID NO: 183.
- the following elements are characterized by a prefix: p- (promoter),: c- (coding sequence), t- ( terminator).
- Table 4C Position of the region of the binary vector pSUN-d15Des (Nh) 2 (16097 bp, DNA, circular), which encodes the desaturase d15Des (Nh) 2 (SEQ ID NO: 6), as well as the position of the expression regulatory regulator Promotors and Terminators.
- the underlying basis vector is pSUN.
- the position indicated describes the start and end point of the corresponding element in base pairs (bp) with reference to SEQ ID NO: 184.
- the following elements are given by characterizes a prefix: p- (promoter),: c- (coding sequence), t- (terminator).
- Example 5 Production of transgenic plants for the production of long-chain polyunsaturated fatty acids.
- the PCR products are incubated for 4 h at 37 0 C with the restriction enzyme Notl.
- the plant expression vector pSUN300-USP is incubated in the same way.
- the PCR products and the 7624 bp vector are separated by agarose gel electrophoresis and the corresponding DNA fragments are excised.
- the purification of the DNA is carried out using Qiagen gel purification kit according to manufacturer's instructions.
- vector and PCR products are ligated. To do this, Roche's Rapid Ligation Kit is used. The resulting plasmids are verified by sequencing.
- pSUN300 is a derivative of the plasmid pPZP (Hajdukiewicz, P, Svab, Z, Maliga, P., (1994) The small versatile pPZP family of Agrobacterium binary vectors for plant transformation, Plant Mol Biol 25: 989-994).
- pSUN-USP was generated from pSUN300 by inserting into pSUN300 a USP promoter as an EcoRI fragment.
- the polyadenylation signal is that of the OCS gene from the A.
- tumefaciens Ti plasmid (ocs terminator, Genbank Accession V00088) (De Greve, H., Dhaese, P., Seurinck, J., Lemmers, M., Van Montagu, M. and Schell, J. Nucleotide sequence and transcript map of the Agrobacterium tumefaciens Ti plasmid-encoded octopine synthase gene J. Mol.
- the USP promoter corresponds to the nucleotides 1 to 684 (Genbank Accession X56240), where part of the non-coding region of the USP gene is contained in the promoter
- the 684 base pair promoter fragment was detected by commercially available T7 standard primer (Stratagene) and by a synthesized primer via a PCR reaction Standard methods amplified.
- the PCR fragment was rescored with EcoRI / SalI and inserted into the vector pSUN300 with OCS terminator.
- the result was the plasmid with the name pSUN-USP, which can be used for the plant transformation by means of Agrobacterium tumefaciens.
- binary vectors such as the pSUN plasmids described above were transformed with the correspondingly combined genes into Agrobacterium tumefaciens C58C1: pGV2260 (Deblaere et al., 1984, Nucl. Acids. Res. 13, 4777-4788).
- the production of plants is to be transformed containing the construct LJB765 (SEQ ID 137) containing a d15 desaturase and a d12 desaturase (elements c-d15Des (Fm_GA) with SEQ ID NO: 140 and c-d12 Des (Co) with SEQ ID NO: 141 in below in Table 8 below).
- the d15-desaturase or d12 desaturase used in the construct can be replaced by the d15-desaturases or d12 desaturases according to the invention.
- the binary vector LJB765 with SEQ ID NO: 137 contains the elements listed in Table 8.
- Table 8 Description of the binary vector LJB765: (28346 bp, DNA, circular). The given position describes the start and end point of the corresponding element in base pairs (bp) with reference to SEQ ID NO: 137. The following elements are characterized by a prefix: c- (coding sequence), o- (replication surpr), p- (Promoter), t- (terminator).
- Regenerated shoots were obtained on 2MS medium with kanamycin and claforan, transferred into soil after rooting and grown in a climatic chamber or greenhouse after cultivation for two weeks, flowered, harvested mature seeds, and expression of desaturase and elon gase, respectively Genes by lipid analysis as exemplified in Qiu et al. 2001, J. Biol. Chem. 276, 31561-31566.
- Figure 2 shows a chromatogram of rapeseed seeds harvested from plants transformed with the construct LJB765. The production of new fatty acids in the rapeseed can be observed. These new fatty acids are due to the activity of the introduced genes (see EPA, eicosapentaenoic acid).
- the seeds of the transgenic plant show increased levels of d12-desaturated product (C18: 2n-6, linoleic acid) and d15-desatured products (18: 3n-3; 18: 4n-3 , EPA) due to the activity of the introduced d12 and d15 desaturase.
- 18.4% omega3 fatty acids could be produced, including 1, 8% EPA, 3.0% 18: 4n-3 and 3.6% 18: 3n-3.
- the untransformed control plant contains between 5 and 6% omega3 fatty acids, i. In the transgenic plants, the content of omega3 fatty acids was tripled.
- construct LJB765 was transformed into Arabidopsis thaliana.
- floral dip method of (Clough and Bent, 1998, Plant Journal 16: 735-743) was used.
- Transgenic plants were selected on agar plates with kanamycins and according to Sayanova et al., 2003, FEBS Letters, 542, 1-104, the harvested seeds were analyzed by gas chromatographic analysis. In this case, similar values were obtained as in oilseed rape (FIG. 3). Compared to the untransformed control, the seeds of the transgenic plant show increased levels of d12-desaturated product (C18: 2n-6, linoleic acid).
- the transformed plants also show a significantly increased content (ie a doubling) of omega3 fatty acids compared to non-transformed plants. For example, 13.7% EPA was obtained. Overall, could 28.6% omega3 fatty acids, of which 13.7% EPA, 0.6% 18: 3n-3, 13.3% 18: 3n-3 and 1, 0% 20: 4n-3.
- d12- and d15-desaturases according to the invention can also be characterized and used for the preparation of polyunsaturated long-chain omega3 fatty acids (such as eicosapentaenoic acid and / or docosahexanoic acid).
- polyunsaturated long-chain omega3 fatty acids such as eicosapentaenoic acid and / or docosahexanoic acid.
- transgenic flax plants The production of transgenic flax plants can, for example, according to the
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112008001989T DE112008001989A5 (de) | 2007-07-31 | 2008-07-30 | Desaturasen und Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen Organismen |
EP08802946A EP2176433B1 (de) | 2007-07-31 | 2008-07-30 | Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen |
US12/671,090 US8785163B2 (en) | 2007-07-31 | 2008-07-30 | Desaturases and methods for producing polyunsaturated fatty acids in transgenic organisms |
AU2008281754A AU2008281754B2 (en) | 2007-07-31 | 2008-07-30 | Desaturases and methods for producing polyunsaturated fatty acids in transgenic organisms |
PL08802946T PL2176433T3 (pl) | 2007-07-31 | 2008-07-30 | Desaturazy i sposób przygotowania wielokrotnie nienasyconych kwasów tłuszczowych w organizmach transgenicznych |
AT08802946T ATE528412T1 (de) | 2007-07-31 | 2008-07-30 | Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen |
CA2694661A CA2694661C (en) | 2007-07-31 | 2008-07-30 | Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113506 | 2007-07-31 | ||
EP07113506.5 | 2007-07-31 | ||
EP07123864.6 | 2007-12-20 | ||
EP07123864 | 2007-12-20 | ||
EP08103294.8 | 2008-04-01 | ||
EP08103294 | 2008-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009016202A2 true WO2009016202A2 (de) | 2009-02-05 |
WO2009016202A3 WO2009016202A3 (de) | 2009-06-18 |
Family
ID=39924986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/059999 WO2009016202A2 (de) | 2007-07-31 | 2008-07-30 | Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen |
Country Status (8)
Country | Link |
---|---|
US (1) | US8785163B2 (de) |
EP (1) | EP2176433B1 (de) |
AT (1) | ATE528412T1 (de) |
AU (1) | AU2008281754B2 (de) |
CA (1) | CA2694661C (de) |
DE (1) | DE112008001989A5 (de) |
PL (1) | PL2176433T3 (de) |
WO (1) | WO2009016202A2 (de) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009130291A2 (de) * | 2008-04-25 | 2009-10-29 | Basf Plant Science Gmbh | Pflanzensamenöl |
WO2010023202A3 (en) * | 2008-08-26 | 2010-06-24 | Basf Plant Science Gmbh | Nucleic acids encoding desaturases and modified plant oil |
WO2010142522A2 (en) | 2009-06-08 | 2010-12-16 | Basf Plant Science Company Gmbh | Novel fatty acid elongation components and uses thereof |
WO2011006948A1 (en) | 2009-07-17 | 2011-01-20 | Basf Plant Science Company Gmbh | Novel fatty acid desaturases and elongases and uses thereof |
WO2011023539A1 (en) | 2009-08-31 | 2011-03-03 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
WO2011023800A1 (en) | 2009-08-31 | 2011-03-03 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific gene expression in plants promoting enhanced polyunsaturated fatty acid synthesis |
WO2011064181A1 (en) | 2009-11-24 | 2011-06-03 | Basf Plant Science Company Gmbh | Novel fatty acid desaturase and uses thereof |
WO2011064183A1 (en) | 2009-11-24 | 2011-06-03 | Basf Plant Science Company Gmbh | Novel fatty acid elongase and uses thereof |
WO2011161093A1 (en) | 2010-06-25 | 2011-12-29 | Basf Plant Science Company Gmbh | Acyltransferases and uses therof in fatty acid production |
WO2012052468A2 (en) | 2010-10-21 | 2012-04-26 | Basf Plant Science Company Gmbh | Novel fatty acid desaturases, elongases, elongation components and uses therof |
EP2481799A1 (de) * | 2009-09-24 | 2012-08-01 | Kyushu University, National University Corporation | Verfahren zur umwandlung von stramenopil |
DE112011104038T5 (de) | 2010-12-06 | 2013-09-12 | Basf Plant Science Company Gmbh | Verfahren zur Herstellung synthetischer Promotoren mit definierter Spezifität |
WO2013185184A2 (en) | 2012-06-15 | 2013-12-19 | Commonwealth Scientific And Industrial Research Organisation | Production of long chain polyunsaturated fatty acids in plant cells |
WO2014020533A2 (en) | 2012-08-03 | 2014-02-06 | Basf Plant Science Company Gmbh | Novel enzymes, enzyme components and uses thereof |
EP2821492A2 (de) | 2009-05-13 | 2015-01-07 | BASF Plant Science Company GmbH | Acyltransferasen und Verwendungen davon zur Fettsäureherstellung |
US9718759B2 (en) | 2013-12-18 | 2017-08-01 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
US9828607B2 (en) | 2009-08-31 | 2017-11-28 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing constitutive gene expression in plants |
US10005713B2 (en) | 2014-06-27 | 2018-06-26 | Commonwealth Scientific And Industrial Research Organisation | Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the sn-2 position |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2743880C (en) | 2008-11-18 | 2020-08-18 | James Robertson Petrie | Recombinant cells comprising exogenous a5 elongase and methods for producing docosapentaenoic acid |
CN105518133A (zh) * | 2013-07-05 | 2016-04-20 | 巴斯夫植物科学有限公司 | 基因表达或活性增强性元件 |
JP2016165226A (ja) * | 2013-07-12 | 2016-09-15 | 国立大学法人京都大学 | エイコサペンタエン酸を高含有する脂質の生産方法 |
JP6197968B1 (ja) * | 2015-12-25 | 2017-09-20 | 東レ株式会社 | 構造体の製造方法 |
CN113854161B (zh) * | 2021-09-29 | 2023-06-09 | 国能龙源环保南京有限公司 | 用于奶牛垫床的沼渣灭菌装置 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075183A (en) * | 1997-04-11 | 2000-06-13 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
WO2003099216A2 (en) * | 2002-05-22 | 2003-12-04 | Monsanto Technology Llc | Fatty acid desaturases from fungi |
US20060094090A1 (en) * | 2004-11-04 | 2006-05-04 | Damude Howard G | Mortierella alpina lysophosphatidic acid acyltransferase homolog for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms |
US20060115881A1 (en) * | 2004-11-04 | 2006-06-01 | Damude Howard G | High eicosapentaenoic acid producing strains of Yarrowia lipolytica |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2012025C (en) | 1989-03-14 | 1999-09-07 | Yukiko Tsukuda | Dna for expression and secretion |
-
2008
- 2008-07-30 AU AU2008281754A patent/AU2008281754B2/en not_active Ceased
- 2008-07-30 PL PL08802946T patent/PL2176433T3/pl unknown
- 2008-07-30 AT AT08802946T patent/ATE528412T1/de active
- 2008-07-30 DE DE112008001989T patent/DE112008001989A5/de not_active Withdrawn
- 2008-07-30 EP EP08802946A patent/EP2176433B1/de not_active Not-in-force
- 2008-07-30 WO PCT/EP2008/059999 patent/WO2009016202A2/de active Application Filing
- 2008-07-30 CA CA2694661A patent/CA2694661C/en not_active Expired - Fee Related
- 2008-07-30 US US12/671,090 patent/US8785163B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075183A (en) * | 1997-04-11 | 2000-06-13 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
WO2003099216A2 (en) * | 2002-05-22 | 2003-12-04 | Monsanto Technology Llc | Fatty acid desaturases from fungi |
US20060094090A1 (en) * | 2004-11-04 | 2006-05-04 | Damude Howard G | Mortierella alpina lysophosphatidic acid acyltransferase homolog for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms |
US20060115881A1 (en) * | 2004-11-04 | 2006-06-01 | Damude Howard G | High eicosapentaenoic acid producing strains of Yarrowia lipolytica |
Non-Patent Citations (2)
Title |
---|
OURA TAKAHIRO ET AL: "Saccharomyces kluyveri FAD3 encodes an omega3 fatty acid desaturase" MICROBIOLOGY (READING), Bd. 150, Nr. Part 6, Juni 2004 (2004-06), Seiten 1983-1990, XP002503090 ISSN: 1350-0872 * |
WONGWATHANARAT P ET AL: "Two fatty acid DELTA9-desaturase genes, ole1 and ole2, from Mortierella alpina complement the yeast ole1 mutation" MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, Bd. 145, Nr. 10, 1. Oktober 1999 (1999-10-01), Seiten 2939-2946, XP002352108 ISSN: 1350-0872 * |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455035B2 (en) | 2008-04-25 | 2013-06-04 | Basf Plant Science Gmbh | Plant seed oil |
WO2009130291A3 (de) * | 2008-04-25 | 2010-05-06 | Basf Plant Science Gmbh | Pflanzensamenöl |
WO2009130291A2 (de) * | 2008-04-25 | 2009-10-29 | Basf Plant Science Gmbh | Pflanzensamenöl |
WO2010023202A3 (en) * | 2008-08-26 | 2010-06-24 | Basf Plant Science Gmbh | Nucleic acids encoding desaturases and modified plant oil |
US9090902B2 (en) | 2008-08-26 | 2015-07-28 | Basf Plant Science Gmbh | Nucleic acids encoding desaturases and modified plant oil |
US9828589B2 (en) | 2009-05-13 | 2017-11-28 | Basf Plant Science Company Gmbh | Acyltransferases and uses thereof in fatty acid production |
US9212371B2 (en) | 2009-05-13 | 2015-12-15 | Basf Plant Science Company Gmbh | Acyltransferases and uses thereof in fatty acid production |
EP2821492A2 (de) | 2009-05-13 | 2015-01-07 | BASF Plant Science Company GmbH | Acyltransferasen und Verwendungen davon zur Fettsäureherstellung |
DE112010002353T5 (de) | 2009-06-08 | 2012-08-09 | Basf Plant Science Company Gmbh | Neue fettsäure-elongations-komponenten und anwenduingen davon |
WO2010142522A2 (en) | 2009-06-08 | 2010-12-16 | Basf Plant Science Company Gmbh | Novel fatty acid elongation components and uses thereof |
US8993841B2 (en) | 2009-06-08 | 2015-03-31 | Basf Plant Science Company Gmbh | Fatty acid elongation components and uses thereof |
WO2011006948A1 (en) | 2009-07-17 | 2011-01-20 | Basf Plant Science Company Gmbh | Novel fatty acid desaturases and elongases and uses thereof |
DE112010002967T5 (de) | 2009-07-17 | 2012-10-11 | Basf Plant Science Company Gmbh | Neue Fettsäuredesaturasen und -elongasen und Anwendungen davon |
US10041081B2 (en) | 2009-08-31 | 2018-08-07 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
EP3121283A1 (de) | 2009-08-31 | 2017-01-25 | BASF Plant Science Company GmbH | Regulatorische nukleinsäuremoleküle für erhöhte samenspezifische genexpression bei pflanzen, welche die erhöhte synthese von mehrfach ungesättigten fettsäuren unterstützen |
US9428757B2 (en) | 2009-08-31 | 2016-08-30 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific gene expression in plants promoting enhanced polyunsaturated fatty acid synthesis |
WO2011023539A1 (en) | 2009-08-31 | 2011-03-03 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
US11708578B2 (en) | 2009-08-31 | 2023-07-25 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing constitutive gene expression in plants |
US10041082B2 (en) | 2009-08-31 | 2018-08-07 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
US10041083B2 (en) | 2009-08-31 | 2018-08-07 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
WO2011023800A1 (en) | 2009-08-31 | 2011-03-03 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific gene expression in plants promoting enhanced polyunsaturated fatty acid synthesis |
US9970019B2 (en) | 2009-08-31 | 2018-05-15 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
US9828607B2 (en) | 2009-08-31 | 2017-11-28 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing constitutive gene expression in plants |
DE112010003493T5 (de) | 2009-08-31 | 2012-06-21 | Basf Plant Science Company Gmbh | Regulatorische Nukleinsäuremoleküle für die Verstärkung der samenspeziflschen und/oder samenpräferentielen Genexpression in Pflanzen |
EP3178937A1 (de) | 2009-08-31 | 2017-06-14 | BASF Plant Science Company GmbH | Regulatorische nukleinsäuremoleküle zur erhöhung der samenspezifischen genexpression bei pflanzen,welche die synthese von mehrfach ungesättigten fettsäuren begünstigen |
EP3418387A1 (de) | 2009-08-31 | 2018-12-26 | Basf Plant Science Company GmbH | Regulatorische nukleinsäuremoleküle zur erhöhung der samenspezifischen genexpression in pflanzen zur förderung der erhöhten synthese von mehrfach ungesättigten fettsäuren |
US10689657B2 (en) | 2009-08-31 | 2020-06-23 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing constitutive gene expression in plants |
US9150871B2 (en) | 2009-08-31 | 2015-10-06 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
US10815505B2 (en) | 2009-09-24 | 2020-10-27 | Kyushu University, National University Corporation | Microbial oil extracted from stramenopiles |
EP2966169A1 (de) * | 2009-09-24 | 2016-01-13 | Kyushu University | Verfahren zur umwandlung von stramenopilen |
CN105368726A (zh) * | 2009-09-24 | 2016-03-02 | 国立大学法人九州大学 | 原生藻菌的转化方法 |
JP5894794B2 (ja) * | 2009-09-24 | 2016-03-30 | 国立大学法人九州大学 | ストラメノパイルの形質転換方法 |
EP2481799A1 (de) * | 2009-09-24 | 2012-08-01 | Kyushu University, National University Corporation | Verfahren zur umwandlung von stramenopil |
EP2481799A4 (de) * | 2009-09-24 | 2013-08-07 | Univ Kyushu Nat Univ Corp | Verfahren zur transformation von stramenopilen |
JPWO2011037207A1 (ja) * | 2009-09-24 | 2013-02-21 | 国立大学法人九州大学 | ストラメノパイルの形質転換方法 |
US9388436B2 (en) | 2009-11-24 | 2016-07-12 | Basf Plant Science Company Gmbh | Fatty acid desaturase and uses thereof |
US9347049B2 (en) | 2009-11-24 | 2016-05-24 | Basf Plant Science Company Gmbh | Fatty acid elongase and uses thereof |
WO2011064181A1 (en) | 2009-11-24 | 2011-06-03 | Basf Plant Science Company Gmbh | Novel fatty acid desaturase and uses thereof |
WO2011064183A1 (en) | 2009-11-24 | 2011-06-03 | Basf Plant Science Company Gmbh | Novel fatty acid elongase and uses thereof |
WO2011161093A1 (en) | 2010-06-25 | 2011-12-29 | Basf Plant Science Company Gmbh | Acyltransferases and uses therof in fatty acid production |
DE112011103527T5 (de) | 2010-10-21 | 2013-10-17 | Basf Plant Science Company Gmbh | Neue Fettsäure-Desaturasen, -Elongasen, -Elongations-Komponenten und Anwendungen davon |
US9458477B2 (en) | 2010-10-21 | 2016-10-04 | Basf Plant Science Company Gmbh | Fatty acid desaturases, elongases, elongation components and uses thereof |
EP2695936A1 (de) | 2010-10-21 | 2014-02-12 | BASF Plant Science Company GmbH | Neue Fettsäuredesaturasen und Verwendungen davon |
WO2012052468A2 (en) | 2010-10-21 | 2012-04-26 | Basf Plant Science Company Gmbh | Novel fatty acid desaturases, elongases, elongation components and uses therof |
US9834778B2 (en) | 2010-12-06 | 2017-12-05 | Basf Plant Science Company Gmbh | Synthetic arcelin-5 promoter and methods of use thereof |
US10072269B2 (en) | 2010-12-06 | 2018-09-11 | Basf Plant Science Company Gmbh | Synthetic promoter and methods of use thereof |
DE112011104038T5 (de) | 2010-12-06 | 2013-09-12 | Basf Plant Science Company Gmbh | Verfahren zur Herstellung synthetischer Promotoren mit definierter Spezifität |
WO2013185184A2 (en) | 2012-06-15 | 2013-12-19 | Commonwealth Scientific And Industrial Research Organisation | Production of long chain polyunsaturated fatty acids in plant cells |
US9932541B2 (en) | 2012-06-15 | 2018-04-03 | Commonwealth Scientific And Industrial Research Organisation | Process for producing ethyl esters of polyunsaturated fatty acids |
US8946460B2 (en) | 2012-06-15 | 2015-02-03 | Commonwealth Scientific And Industrial Research Organisation | Process for producing polyunsaturated fatty acids in an esterified form |
US9999607B2 (en) | 2012-06-15 | 2018-06-19 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising polyunsaturated fatty acids |
US11834621B2 (en) | 2012-06-15 | 2023-12-05 | Nuseed Global Innovation Ltd. | Lipid comprising polyunsaturated fatty acids |
US9550718B2 (en) | 2012-06-15 | 2017-01-24 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising polyunsaturated fatty acids |
US9932289B2 (en) | 2012-06-15 | 2018-04-03 | Commonwealth Scientific And Industrial Research Ogranisation | Process for producing ethyl esters of polyunsaturated fatty acids |
US10899992B2 (en) | 2012-06-15 | 2021-01-26 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising polyunsaturated fatty acids |
US9932290B2 (en) | 2012-06-15 | 2018-04-03 | Commonwealth Scientific And Industrial Research Organisation | Process for producing ethyl esters of polyunsaturated fatty acids |
US11306271B2 (en) | 2012-06-15 | 2022-04-19 | Commonwealth Scientific And Industrial Research Organisation | Process for producing extracted lipid comprising docosahexaenoic acid |
EP3266316A1 (de) | 2012-06-15 | 2018-01-10 | Commonwealth Scientific and Industrial Research Organisation | Herstellung von langkettigen, mehrfach ungesättigten fettsäuren in pflanzenzellen |
US9969954B2 (en) | 2012-06-15 | 2018-05-15 | Commonwealth Scientific And Industrial Research Organisation | Oil comprising polyunsaturated fatty acids |
US10335386B2 (en) | 2012-06-15 | 2019-07-02 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising polyunsaturated fatty acids |
US10655082B2 (en) | 2012-06-15 | 2020-05-19 | Commonwealth Scientific And Industrial Research Organisation | Oil comprising polyunsaturated fatty acids |
WO2014020533A2 (en) | 2012-08-03 | 2014-02-06 | Basf Plant Science Company Gmbh | Novel enzymes, enzyme components and uses thereof |
US10190073B2 (en) | 2013-12-18 | 2019-01-29 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising long chain polyunsaturated fatty acids |
US10800729B2 (en) | 2013-12-18 | 2020-10-13 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising long chain polyunsaturated fatty acids |
US9725399B2 (en) | 2013-12-18 | 2017-08-08 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising long chain polyunsaturated fatty acids |
US10125084B2 (en) | 2013-12-18 | 2018-11-13 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
US11623911B2 (en) | 2013-12-18 | 2023-04-11 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
US9718759B2 (en) | 2013-12-18 | 2017-08-01 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
US10793507B2 (en) | 2014-06-27 | 2020-10-06 | Commonwealth Scientific And Industrial Research Organisation | Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the SN-2 position |
US10005713B2 (en) | 2014-06-27 | 2018-06-26 | Commonwealth Scientific And Industrial Research Organisation | Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the sn-2 position |
Also Published As
Publication number | Publication date |
---|---|
AU2008281754A1 (en) | 2009-02-05 |
CA2694661C (en) | 2017-10-03 |
PL2176433T3 (pl) | 2012-04-30 |
EP2176433B1 (de) | 2011-10-12 |
US20100199365A1 (en) | 2010-08-05 |
AU2008281754B2 (en) | 2014-07-24 |
CA2694661A1 (en) | 2009-02-05 |
WO2009016202A3 (de) | 2009-06-18 |
US8785163B2 (en) | 2014-07-22 |
ATE528412T1 (de) | 2011-10-15 |
EP2176433A2 (de) | 2010-04-21 |
DE112008001989A5 (de) | 2010-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2166067B1 (de) | Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen Organismen | |
EP2176433B1 (de) | Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen | |
EP2182056B1 (de) | Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen nicht-humanen Organismen | |
EP1720988B1 (de) | Verfahren zur herstellung von ungesättigten omega-3-fettsäuren in transgenen organismen | |
EP2176416B1 (de) | Elongasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen | |
WO2006008099A2 (de) | Verfahren zur erhöhung des gehalts an mehrfach ungesättigten langkettigen fettsäuren in transgenen organismen | |
WO2006069710A1 (de) | Verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen | |
DE112009003708T5 (de) | Desaturasen und Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenenOrganismen | |
WO2008104559A1 (de) | Verfahren zur herstellung von mehrfach ungesättigten fettsäuren in transgenen organismen | |
Senger et al. | Desaturases And Process For The Production Of Polyunsaturated Fatty Acids In Transgenic Organisms (Patent EP 2669380 B1) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08802946 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2694661 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12671090 Country of ref document: US Ref document number: 2008802946 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008281754 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2008281754 Country of ref document: AU Date of ref document: 20080730 Kind code of ref document: A |
|
REF | Corresponds to |
Ref document number: 112008001989 Country of ref document: DE Date of ref document: 20100610 Kind code of ref document: P |